File No. <u>210684</u>

Committee Item No. _7____ Board Item No. _____

COMMITTEE/BOARD OF SUPERVISORS


AGENDA PACKET CONTENTS LIST

Committee: <u>Government Audit and Oversight</u> Board of Supervisors Meeting: Date: June 23, 2021
Date:

Cmte Board

	Motion
\boxtimes	Resolution
	Ordinance
	Legislative Digest
	Budget and Legislative Analyst Report
	Youth Commission Report
	Introduction Form
\bowtie	Department/Agency Cover Letter and/or Report
	MÓU
\mathbb{X}	Grant Information Form
\boxtimes	Grant Budget
	Subcontract Budget
	Contract/Agreement
	Form 126 – Ethics Commission
	Award Letter
	Application
	Public Correspondence

OTHER



Prepared by:	John Carroll
Prepared by:	John Carroll
Prepared by:	John Carroll

Date:	June 18, 2021	
Date:		
Date:		

- [Accept and Expend Grant Retroactive Centers for Disease Control and Prevention -Targeted Human Immunodeficiency Virus/Tuberculosis Strategic Information Technical Assistance - \$127,696]
- 3

4 Resolution retroactively authorizing the Department of Public Health to accept and 5 expend a grant amendment to increase the amount of \$57,564 for a total of \$127,696 6 from the Centers for Disease Control and Prevention through the Regents of the 7 University of California, San Francisco for participation in a program, entitled 8 "Targeted Human Immunodeficiency Virus/Tuberculosis Strategic Information 9 Technical Assistance for President's Emergency Plan for Acquired Immunodeficiency 10 Syndrome Relief (PEPFAR) and Global Fund to Fight Acquired Immunodeficiency 11 Syndrome, Tuberculosis and Malaria (GFATM) Countries," for the period of 12 September 30, 2019, through September 29, 2021.

13

14 WHEREAS, The Centers for Disease Control and Prevention (CDC), through the 15 Regents of the University of California, San Francisco (UCSF) as a pass-through entity, has 16 agreed to fund the Department of Public Health (DPH) in the amount of \$127,696 for 17 participation in a program, entitled "Targeted Human Immunodeficiency Virus/Tuberculosis 18 (HIV/TB) Strategic Information Technical Assistance for President's Emergency Plan for 19 Acquired Immunodeficiency Syndrome (AIDS) Relief (PEPFAR) and Global Fund to Fight 20 AIDS, Tuberculosis and Malaria (GFATM) Countries," for the period of September 30, 2019, 21 through September 29, 2021; and 22 WHEREAS, DPH will support Myanmar Project needs; and 23 WHEREAS, As part of the scope of work, DPH will provide technical assistance on

24 Human Immunodeficiency Virus (HIV) surveillance related activities and facilitate or co-

25 facilitate in-country trainings and workshops; and

WHEREAS, DPH will be responsible for developing study and training materials; and
 WHEREAS, A grant increase of \$57,564 from \$70,132 was approved for the period of
 September 30, 2020, through September 29, 2021; and

- WHEREAS, The grant does not require an Annual Salary Ordinance Amendment; and
 WHEREAS, A request for retroactive approval is being sought because DPH received
 the full award agreement on February 8, 2021, for a project start date of September 30, 2019;
 and
- 8 WHEREAS, The grant includes a provision for indirect costs in the amount of \$13,681; 9 now, therefore, be it
- 10 RESOLVED, That DPH is hereby authorized to retroactively accept and expend a grant
 11 in the amount of \$127,696 from the CDC through the UCSF; and, be it
- 12 FURTHER RESOLVED, That DPH is hereby authorized to retroactively accept and
- 13 expend the grant funds pursuant to Administrative Code, Section 10.170-1; and, be it
- FURTHER RESOLVED, That the Director of Health is authorized to enter into theAgreement on behalf of the City; and, be it
- FURTHER RESOLVED, That within thirty (30) days of the Grant Agreement being fully executed by all parties, the Director of Health shall provide a copy to the Clerk of the Board of Supervisors for inclusion in the official file.
- 19
- 20
- 21
- 22
- ___
- 23
- 24
- 25

1	Recommended:	Approved: <u>/s/</u>
2		Mayor
3	<u>/s/</u>	
4	Dr. Grant Colfax	Approved: <u>/s/</u>
5	Director of Health	Controller
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		

File Number:

(Provided by Clerk of Board of Supervisors)

Grant Resolution Information Form

(Effective July 2011)

Purpose: Accompanies proposed Board of Supervisors resolutions authorizing a Department to accept and expend grant funds.

The following describes the grant referred to in the accompanying resolution:

1. Grant Title: Targeted HIV/TB Strategic Information Technical Assistance for President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) Countries

- 2. Department: **Department of Public Health Center of Public Health Research**
- 3. Contact Person: William McFarland Telephone: 415-437-6251
- 4. Grant Approval Status (check one):
 - [X] Approved by funding agency [] Not yet approved
- 5. Amount of Grant Funding Approved or Applied for: **\$127,696** (Year 1: September 30, 2019 - December 31, 2019: **\$17,533** Year 2: January 1, 2020 - February 29, 2020: **\$11,689** Year 3: March 1, 2020 - September 29, 2020: **\$40,910** Year 4: September 30, 2020 - September 29, 2021: **\$57,564**)
- 6a. Matching Funds Required: \$0
- b. Source(s) of matching funds (if applicable): N.A.
- 7a. Grant Source Agency: Centers for Disease Control and Prevention (CDC)
- b. Grant Pass-Through Agency (if applicable): The Regents of the University of California, San Francisco
- 8. Proposed Grant Project Summary:

The SFDPH subcontractor, Dr. William McFarland, will support Myanmar project needs. As part of the scope of work, Dr. McFarland will provide technical assistance on HIV surveillance related activities and facilitate or co-facilitate in-country trainings and workshops. He will also be responsible for developing study and training materials and participate regularly on conference calls and meetings.

9. Grant Project Schedule, as allowed in approval documents, or as proposed:

Start-Date: 09/30/2019 End-Date: 09/29/2021

10a. Amount budgeted for contractual services: N.A.

b. Will contractual services be put out to bid? No

- c. If so, will contract services help to further the goals of the Department's Local Business Enterprise (LBE) requirements? **N.A.**
- d. Is this likely to be a one-time or ongoing request for contracting out? N.A.
- 11a. Does the budget include indirect costs? [X] Yes [] No
 - b1. If yes, how much? \$13,681
 - b2. How was the amount calculated? 12% of total indirect costs
 - c1. If no, why are indirect costs not included? [] Not allowed by granting agency [] Other (please explain):
 - c2. If no indirect costs are included, what would have been the indirect costs? N.A.
- 12. Any other significant grant requirements or comments:

We respectfully request for approval to accept and expend these funds retroactive to September 30, 2019. The Department received the amended subaward agreement on February 08, 2021.

This grant does not require an ASO amendment and partially reimburses the Department for one position: one Supervising Physician Specialist (Job Class #2233) at 0.25 FTE during the period of September 30, 2019 through September 29, 2021.

Fund ID:11580Department ID:162646Authority ID:10001Project Desc:HD HIV PD123 2021 UCSF 11626sc Targeted HIV/TB Strategic InformationTechnical Assistance BurmaProject ID:10037638Activity ID:0001

Disability Access Checklist*(Department must forward a copy of all completed Grant Information Forms to the Mayor's Office of Disability)

13. This Grant is intended for activities at (check all that apply):

[X] Existing Site(s)	[] Existing Structure(s)
[] Rehabilitated Site(s)	[] Rehabilitated Structure(s)
[] New Site(s)	[] New Structure(s)

[] Existing Program(s) or Service(s) [] New Program(s) or Service(s)

14. The Departmental ADA Coordinator or the Mayor's Office on Disability have reviewed the proposal and concluded that the project as proposed will be in compliance with the Americans with Disabilities Act and all other Federal, State and local disability rights laws and regulations and will allow the full inclusion of persons with disabilities. These requirements include, but are not limited to:

1. Having staff trained in how to provide reasonable modifications in policies, practices and procedures;

2. Having auxiliary aids and services available in a timely manner in order to ensure communication access;

3. Ensuring that any service areas and related facilities open to the public are architecturally accessible and have been inspected and approved by the DPW Access Compliance Officer or the Mayor's Office on Disability Compliance Officers.

If such access would be technically infeasible, this is described in the comments section below:

Comments:

Departmental ADA Coordinator or Mayor's Office of Disability Reviewer:

Toni Rucker, PhD			
(Name)			
DPH ADA Coordinator			
(Title)		DocuSigned by:	-
Date Reviewed:	5/13/2021 4:04 PM PDT	toni Rucker	
		(Signature Required)	_

Department Head or Designee Approval of Grant Information Form:

Dr. Grant Colfax	
(Name)	
Director of Health	
(Title)	Greg Wagner
Date Reviewed:	
	(Signature Required)
	Greg Wagner, COO for

Amendment No. 3 to Agreement No. 11626sc Between The Regents of the University of California And City and County of San Francisco Prime Grant Number: 1 NU2GGH002183

This Agreement between the Regents of the University of California, on behalf of its San Francisco Campus ("UCSF") and City and County of San Francisco ("Subrecipient") for the project "" is amended as follows:

Article I – Scope of Work

Subrecipient's scope of work is updated as revised and incorporated in Attachment A.

Article III – Period of Performance

The period of performance is September 30, 2020 through September 29, 2021.

Article IV – Compensation

Additional funding in the amount of \$57,564 is awarded in accordance with Attachment B for the term referenced in Article III, above. Carryover across budget periods requires prior approval. Carry Forward requests must be sent to UCSF's Principal Investigator for approval.

Attachment A - Scope of Work

Attachment B - Budget

Attachment C - Award

All other terms and conditions of the Agreement remain in full force and effect.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment on the month, day, and year specified below.

For: The Regents of the University of California

-Docusigned by: Phillip De Biase

Name:Phillip De Biase Title: Associate Manager, Subcontracts Date: 2/8/2021 For: City and County of San Francisco

DocuSigned by: Greg Wagner

Name: Greg Wagner Title: Chief Financial Officer

Date: 2/8/2021 | 11:06 AM PST

Attachment A

Appendix A: San Francisco Department of Public Health (SFDPH):

1. Name of Contractor: San Francisco Department of Public Health (SFDPH).

2. Method of Selection: The San Francisco Department of Public Health has a wellestablished reputation in conducting state of the art surveillance in HIV/AIDS and is a world leader in second and third generation HIV surveillance methodologies with extensive experience in implementing these methodologies and providing training in this field. SFDPH also has one of the world's most innovative and sophisticated HIV casebased surveillance systems and has hosted many tours of their system from partners around the globe. Their experience in conducting training in local, national, and international institutions within the US and in many countries overseas is of particular importance to the successful completion of this project. Finally, UCSF and SFDPH have a successful history of collaboration in the area of providing technical assistance on HIV surveillance in collaboration within our unit for CDC/PEFPAR projects and in providing TA in SI throughout Central and Southeast Asia.

3. Period of Performance: September 30, 2020 to September 29, 2021

4. Scope of Work: The SFDPH subcontractor, Dr. Willi McFarland, will support Myanmar project needs. As part of the scope of work, Dr. McFarland will provide technical assistance on HIV surveillance and HIV research related activities and facilitate or co-facilitate in-country trainings and workshops. He will also be responsible for developing study and training materials and participate regularly on conference calls and meetings.

5. Method of Accountability: Subrecipients are contractually required to report regularly on programmatic progress and financial status. UCSF routinely monitors subrecipient progress in all elements of the Scope of Work. Subcontract agreements at UCSF are established with "not to exceed" amounts and payments are issued only upon

receipt of invoices, which are reviewed and approved by UCSF project staff.

6. Itemized Budget and Justification: Begins next page

Attachment B

Appendix A (continued) San Francisco Department of Public Health (SFDPH): Detailed Budget and Justification

Salaries and Wages:

Willi McFarland, MD, PhD, MPH&TM, Director of Surveillance, Professor and Faculty Advisor, UCSF and Director of the Center for Public Health Research at SFDPH, will provide technical assistance on all surveillance planning and implementation activities in Myanmar, and lead in-country technical trainings/workshops. We request 20% (\$39,460) salary support for this position for 12 months.

Fringe Benefit:

Total: \$11,937

The fringe benefit rate for this subcontract is calculated as follows:

	Salary Requested	<u>% Benefit Rate</u>	Total Fringe Benefits
McFarland, Willi	\$ 39,460	30.25%	\$ 11,937

Total Direct Costs

Indirect Cost Rates:

The indirect cost rate is 12% of total direct expenses and is in compliance with the bilateral agreement between UCSF and SFDPH.

Total Cost Requested:

Total: \$57,564

Total: \$39,460

Total: \$6,167

Total: \$51,397

San Francisco Department of Public Health Subcontract Budget Period: 9/30/2020-9/29/2021 Budget Name: SIQHIL Burma YR 2 Continuation Budget

A. Salaries and W	ages				(A)	(B)	
Personnel McFarland, Willi	Position Title Director of Surveillance	Current Salary \$197,300	% effort 20%	# mos. 12	Salary \$39,460	Benefits \$11,937	Total \$51,397 \$0 \$0
Total Personnel			20%)	\$39,460	\$11,937	\$51,397
Total Direct Costs Overhead at 12% Grand Total							\$51,397 <u>\$6,167</u> \$57,564

DocuSign Envelope ID: 9E97992B-7D61-4123-BC00-CAA4B619F285 hment C

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award

Award# 6 NU2GGH002183-02-02 FAIN# NU2GGH002183 Federal Award Date: 12/11/2020

Recipient Information

1. Recipient Name

Regents Of The University Of California, San Francisco, The 1855 Folsom St Ste 425 San Francisco, CA 94143-4249 [No Phone Record]

- 2. Congressional District of Recipient 12
- **3. Payment System Identifier (ID)** 1946036493A6
- **4. Employer Identification Number (EIN)** 946036493
- 5. Data Universal Numbering System (DUNS) 094878337
- 6. Recipient's Unique Entity Identifier

7. Project Director or Principal Investigator

Dr. GEORGE WILLIAMS RUTHERFORD546030 Professor George.Rutherford@ucsf.edu 4154765781

8. Authorized Official

Ms. Magdalene Cho Contracts and Grants Officer maggie.cho@ucsf.edu 415-502-8752

Federal Agency Information CDC Office of Financial Resources

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Mrs. Erica Stewart Grants Management Officer ity9@cdc.gov 770-488-2769

10.Program Official Contact Information

Mrs. Priyanka Rathod PBEMB CoAg Specialist wnv9@cdc.gov 404-718-5243

30. Remarks

Federal Award Information

11. Award Number 6 NU2GGH002183-02-02

- 12. Unique Federal Award Identification Number (FAIN) NU2GGH002183
- **13. Statutory Authority**
 - 42 USC 287b 31 USC 6305 42 CFR 63a
- 14. Federal Award Project Title
 - GH19-1951 Targeted HIV/TB Strategic Information Technical Assistance for President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) Countries
- **15. Assistance Listing Number**
- 93.067 **16. Assistance Listing Program Title**
 - Global AIDS
- 17. Award Action Type
- Component/Project funding 18. Is the Award R&D?

0. 15 t No

Summary Federal Award Financial Information

- **19. Budget Period Start Date** 09/30/2020 End Date 09/29/2021
- **20. Total Amount of Federal Funds Obligated by this Action** 20a. Direct Cost Amount
 - 20b. Indirect Cost Amount
- 21. Authorized Carryover
- 22. Offset
- **23.** Total Amount of Federal Funds Obligated this budget period
- 24. Total Approved Cost Sharing or Matching, where applicable
- 25. Total Federal and Non-Federal Approved this Budget Period
- **26. Project Period Start Date** 09/30/2019 End Date 09/29/2024
- **27.** Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Ms. Shicann Phillips

Lead Grants Management Specialist

DocuSign Envelope ID: 9E97992B-7D61-4123-BC00-CAA4B619F285

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award

Award# 6 NU2GGH002183-02-02 FAIN# NU2GGH002183 Federal Award Date: 12/11/2020

Recipient Information	33. Approved Budget (Excludes Direct Assistance)			
Recipient Name	I. Financial Assistance from the Federal Awarding Agency Only			
Regents Of The University Of California, San	II. Total project costs including grant funds and all other financial participation			
Francisco, The	a. Salaries and Wages			
1855 Folsom St Ste 425	b. Fringe Benefits			
San Francisco, CA 94143-4249	c. TotalPersonnelCosts			
[No Phone Record]				
ongressional District of Recipient	d. Equipment			
12	e. Supplies			
ayment Account Number and Type	f. Travel			
1946036493A6 mployer Identification Number (EIN) Data	g. Construction			
946036493	h. Other			
niversal Numbering System (DUNS) 094878337	i. Contractual			
ecipient's Unique Entity Identifier	j. TOTAL DIRECT COSTS			
Not Available	k. INDIRECT COSTS			
31. Assistance Type	1. TOTAL APPROVED BUDGET			
Cooperative Agreement 32. Type of Award	m. Federal Share			
Demonstration	n. Non-Federal Share			

ADMINISTRATIVE CODE OBJECT CLASS AMT ACTION FINANCIAL ASSISTANCE APPROPRIATION DOCUMENT NO. FY-ACCOUNT NO. 1-939099X 19NU2GGH002183WHCC 75-19-1721-1031-001 GH 41.51 1-93909D9 19NU2GGH00218319ABCO GH 41.51 75-19-1721-1031-001 1-9390BKZ 19NU2GGH00218319ABCO GH 41.51 75-19-1822-1031-001 1-9390BL2 19NU2GGH002183WHCC GH 41.51 75-19-1822-1031-001 75-2122-0955 1-9390FU0 19NU2GGH002183WHCC GH41.51 19NU2GGH002183WHCC 41.51 75-19-X-1031-001 1-939ZLRV GH

DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award



Award# 6 NU2GGH002183-02-02 FAIN# NU2GGH002183 Federal Award Date: 12/11/2020

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

- Centers for Disease Control and Prevention

Award# 6 NU2GGH002183-02-02 FAIN# NU2GGH002183 Federal Award Date: 12/11/2020

35. Terms And Conditions

Federal Financial Report Cycle					
Reporting Period Start Date Reporting Period End Date Reporting Type Reporting Period Due Date					
09/30/2020	09/29/2021	Annual	12/28/2021		

AWARD ATTACHMENTS

Regents Of The University Of California, San Francisco, The

6 NU2GGH002183-02-02

1. Terms and Conditions

2. PO Budget Mark-up

AWARD INFORMATION

Component/Project Funding: The <u>purpose of this revised</u> Notice of Award (NOA) is to award component funding in the amount o he approved component funding levels for this notice of award are:

NOFO Component/Country	Amount	
CRO HIV 3		
CRO HIV4		
Burma Comp 2		

Budget by Project/Activities/Category/Component Funding: Recipients must ensure to track and report project funding and activities by projects. Projects costs cannot be redirected between projects categories/component without prior CDC approval.

Future Component Funding Requirement: For any future component funding, a separate budget along with a budget narrative/justification and workplan is required for each component being funded. Failure to provide the requested information, may negatively affect future funding.

FUNDING RESTRICTIONS AND LIMITATIONS

Use of CDC funding for the Procurement of PPE and other Essential Medical Supplies / Procurement of "Covered Materials":

- Except as provided in paragraph 2, below, and notwithstanding anything in this award to the contrary, no funds under this award may be used for the procurement of "Covered Materials" as listed below without the prior written consent of the Grants Management Officer (GMO) For purposes of this provision, "Covered Materials" shall consist of the following:
 - N95 Filtering Facepiece Respirators, including devices that are disposable halfface-piece non- powered air-purifying particulate respirators intended for use to cover the nose and mouth of the wearer to help reduce wearer exposure to pathogenic biological airborne particulates;
 - Other Filtering Facepiece Respirators (e.g., those designated as N99, N100, R95, R99, R100, P95, P99, or P100), including single-use, disposable half-mask respiratory protective devices that cover the user's airway (nose and mouth) and offer protection from particulate materials at an N95 filtration efficiency level per 42 CFR 84.181;
 - Elastomeric, air-purifying respirators and appropriate particulate filters/cartridges;
 - PPE surgical masks, including masks that cover the user's nose and mouth and provide a physical barrier to fluids and particulate materials;
 - PPE gloves or surgical gloves, including those defined at 21 CFR 880.6250 (exam gloves) and 878.4460 (surgical gloves) and such gloves intended for the same purposes;
 - Ventilators;
 - COVID-19 test kits;
 - Ancillary laboratory reagents; and
 - Specimen collections materials that are meant for the United States market.

For clarity, non-medical grade masks, including cloth masks, are not included in the list of "Covered Materials" above. Further, the list of "Covered Materials" may be modified from time-to-time in writing by the GMO, if changes to the list occur.

- 2. The restrictions set forth in paragraph 1, above, shall not apply to the procurement of Covered Materials under the following circumstances:
 - For the protection of and use by recipient staff; or
 - When such procurements are needed to ensure continuity of safe and effective implementation of health or other public health programs, such items may be procured locally or regionally, provided that such items are not, and could not reasonably be expected to be, meant for the United States market. Recipients must document this determination in their files or records and provide a copy of such documentation to their cognizant GMOs.

The exceptions set forth in this paragraph may be changed by the GMO in writing, as necessary.

When recipients rely on the second exception above regarding the procurement of Covered Material manufactured locally or regionally, they should engage in conversations with vendors and manufacturers to ensure the Covered Material being procured is not, and could not reasonably be, intended for the U.S. market.

Special Provision for HHS Protecting Life in Global Health Assistance is applicable to this award. In accordance with the United States Protecting Life in Global Health Assistance policy, a nongovernmental organization (NGO) recipient of this award acknowledges that foreign NGOs that receive funds provided through this award, either as a prime recipient or subrecipient, are strictly prohibited, regardless of the source of funds, from performing abortions as a method of family planning or engaging in any activity that promotes abortion as a method of family planning, or to provide financial support to any other foreign non-governmental organization that conducts such activities. See Additional Requirement (AR) 35 to ensure compliance with this term and condition. The link to the full text is at: <u>https://www.cdc.gov/grants/federal-regulations-policies/index.html</u>

PAYMENT INFORMATION

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

This award may contain funding from multiple components. The grant document number(s) identified on Page 2 of the Notice of Award and component name.

Country/Component: Burma	
Document Number: 19NU2GGH00218319ABCO	
Country/Component: Caribbean Regional Office (CRO)	

Document Number: 19NU2GGH002183WHCC

Stewardship: Please be advised that the recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to their cooperative agreement are allowable, allocable, necessary, and reasonable.

All other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed in writing, by the Grants Management Officer.

PLEASE REFERENCE AWARD NUMBER ON ALL CORRESPONDENCE

OGS Staff Contacts

GMS Contact: Erica Stewart, Grants Management Specialist Centers for Disease Control and Prevention Branch 3 2939 Flowers Road Atlanta, GA 30341 Email: <u>ity9@cdc.gov</u> Phone 770-488-2769

DGHT Component Funding Budget Mark-Up and Programmatic Restrictions

Country or HQ Branch:				HQ/ Burma and Caribbean					
Recipient:			UCS	F					
NOFO #:			GH1	9-1951					
CoAg Award #:			GH0	02183					
Budget Period Year:			2						
COMPONENT FUNDING BU	IDGET BREAKDOW	N - Enter the o	bject c	lass breakdown for	each component	being funded in the tal	ole below		
Name of Component (set at continuation/new award)	CRO HIV 3	CRO HIV4		Burma Comp 2			TOTAL		
Personnel									
Fringe Benefits	-								
Travel									
Equipment	-								
Supplies	-								
Contractual									
Facilities/Construction									
Other	TOTAL Direct Charges								

Programmatic Budgetary Comments

Marked-Up Budget Certification (select one)

This box signifies the Project Officer's official review of the applicant's proposed budget for the component(s) to be funded. This box also indicates whether a revised budget is required. <u>PBEMB will consider a Component</u> Funding action to be **incomplete** if this box is left unchecked.

The recommended budget should be outlined in the first page of this form for component funding actions.

I certify that I support the recipient's proposed budget submitted in this application as it relates to the technical aspects of the project. No changes are required and no restrictions are recommended.

□ I wish to make changes to the recipient's proposed budget. A revised budget will be required.

If additional space is needed to justify the <u>recommended</u> funding amount and any changes made to the budget, please use this space below to provide detailed comments for the recipient: (*Please use bullets and reference your comments with page numbers from the recipient budget*)

Programmatic Restrictions:

Indicate programmatic restrictions in table below (if applicable): Do not put potential human subjects or IRB restrictions or conditions in this section:

PLEASE NOTE BEFORE COMPLETING RESTRICTIONS:

- Recipients are not always funded at the level of the approved budget period ceiling, generally due to delays in CDC's receipt of funds. As such, do not penalize recipients for not completing unfunded activities.
- When possible, the response to TR should be used as a management tool, as opposed to restricting funds. Funds should only be restricted when absolutely necessary.
- Only include programmatic restrictions that should be put in place for the funding components that will be awarded <u>at this time</u>. If future restrictions are needed, they can be added once future funding components are awarded.

Object Classification	Programmatic Restriction
Salaries	\$
Fringe Benefits	\$
Consultants	\$
Equipment	\$
Supplies	\$
Travel	\$
Other	\$
Contractual	\$
Direct Costs	\$ 0
Indirect Costs	\$
Total	\$ 0

If additional space is needed to justify the <u>programmatic restrictions</u>, please use this space below to provide detailed comments for the recipient:

(Please use bullets and reference your comments with page numbers from the recipient budget)

Not Applicable

San Francisco Department of Public Health Subcontract Budget Period: 9/30/2020-9/29/2021 Budget Name: SIQHIL Burma YR 2 Continuation Budget

A. Salaries and W	ages_				(A)	(B)	
Personnel McFarland, Willi	Position Title Director of Surveillance	Current Salary \$197,300	% effort 20%	# mos. 12	Salary \$39,460	Benefits \$11,937	Total \$51,397 \$0 \$0
Total Personnel			20%)	\$39,460	\$11,937	\$51,397
Total Direct Costs Overhead at 12% Grand Total							\$51,397 <u>\$6,167</u> \$57,564

Attachment B

Appendix A (continued) San Francisco Department of Public Health (SFDPH): Detailed Budget and Justification

Salaries and Wages:

Willi McFarland, MD, PhD, MPH&TM, Director of Surveillance, Professor and Faculty Advisor, UCSF and Director of the Center for Public Health Research at SFDPH, will provide technical assistance on all surveillance planning and implementation activities in Myanmar, and lead in-country technical trainings/workshops. We request 20% (\$39,460) salary support for this position for 12 months.

Fringe Benefit:

Total: \$11,937

The fringe benefit rate for this subcontract is calculated as follows:

	Salary Requested	<u>% Benefit Rate</u>	Total Fringe Benefits
McFarland, Willi	\$ 39,460	30.25%	\$ 11,937

Total Direct Costs

Indirect Cost Rates:

The indirect cost rate is 12% of total direct expenses and is in compliance with the bilateral agreement between UCSF and SFDPH.

Total Cost Requested:

Total: \$57,564

Total: \$39,460

Total: \$6,167

Total: \$51,397

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH

Center of Public Health Research

Targeted HIV/TB Strategic Information Technical Assistance for President's Emergency Plan for AIDS Relief (PEPFAR)

and Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)@ountries"

UCSF# 11626sc_00

September 30, 2019 to December 31, 2019

	Cate	egory/Line Item	Annual Salary	30.25% Annual Frin Ben	Total Annual Sal/Frin Ben		% OF FTE	Monthly Rate	Mth	Salary Budget	Frin Ben Budget	Total Budget
A.	PEI 1.	RSONNEL Sr. Physician Specialist 2233 5 William McFarland	192,300	58,171	250,471	25%	0.25	16,025	3.0	12,019	3,636	15,654
		TOTAL PERSONNEL: 00101 SALARIES:	58,171	250,471		0.25			12,019	3,636	15,654 12,019	
		00103 MANDATORY FRINGE: TOTAL PERSONNEL:										3,636 15,654
TOTAL DIRECT COST										15,654		
			OST (12% o	of Total Dire	ct Cost)							1,879
	TOTAL BUDGET											17,533

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH Center of Public Health Research Targeted HIV/TB Strategic Information Technical Assistancefor President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)@ountries" UCSF# 11626sc_01

January 1, 2020 to February 29, 2020

	Category/Line Item	Annual Salary	30.25% Annual Frin Ben	Total Annual Sal/Frin Ben	% OF TIME	% OF FTE	Monthly Rate	Mth	Salary Budget	Frin Ben Budget	Total Budget
A	A. PERSONNEL										
	1. Sr. Physician Specialist 2233 5 William McFarland	192,300	58,171	250,471	25%	0.25	16,025	2.0	8,013	2,424	10,436
-	TOTAL PERSONNEL:	192,300	58,171	250,471		0.25			8,013	2,424	10,436
00101 SALARIES: 00103 MANDATORY FRINGE: TOTAL PERSONNEL:											8,013 2,424 10,436
TOTAL DIRECT COST									10,436		
	INDIRECT CO	OST (12% o	f Total Dire	ct Cost)							1,252
	TOTAL BUDGET								11,689		

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH Center of Public Health Research Targeted HIV/TB Strategic Information Technical AssistanceBor President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)©ountries" UCSF# 11626sc_02 March 1, 2020 to September 29, 2020

	Category/Line Item	Annual Salary	30.25% Annual Frin Ben	Total Annual Sal/Frin Ben	% OF TIME	% OF FTE	Monthly Rate	Mth	Salary Budget	Frin Ben Budget	Total Budget
,	 PERSONNEL Sr. Physician Specialist 										
	2233 5 William McFarland	192,300	58,171	250,471	20%	25%	16,025	7.0	28,044	8,483	36,527
TOTAL PERSONNEL: 192,300 58,171 250,471									28,044	8,483	36,527
	00101 SALARIES: 00103 MANDATORY FRINGE: TOTAL PERSONNEL:										28,044 8,483 36,527
TOTAL DIRECT COST									36,527		
	INDIRECT CO	OST (12% o	f Total Dire	ct Cost)							4,383
	TOTAL BUDGET								40,910		

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH Center of Public Health Research Targeted HIV/TB Strategic Information Technical Assistancefor President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)@ountries" UCSF# 11626sc_03

September 30, 2020 to September 29, 2021

	Category/Line Item	Annual Salary	30.25% Annual Frin Ben	Total Annual Sal/Frin Ben		% OF FTE	Monthly Rate	Mth	Salary Budget	Frin Ben Budget	Total Budget
A											
	 Sr. Physician Specialist 2233 5 William McFarland 	197,300	59,683	256,983	20%	20%	16,442	12.0	39,460	11,937	51,397
	TOTAL PERSONNEL:	197,300	59,683	256,983		0.20			39,460	11,937	51,397
	00101 SALARIES: 00103 MANDATORY FRINGE: TOTAL PERSONNEL:										39,460 11,937 51,397
TOTAL DIRECT COST								51,397			
		OST (12% o	f Total Dire	ct Cost)							6,168
	TOTAL BUDGET									57,564	

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH Center of Public Health Research Targeted HIV/TB Strategic Information Technical Assistancefor President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)Eountries" UCSF# 11626sc_03 September 30, 2019 to September 29, 2021

Budget Period	Category/Line Item	Annual Salary	30.25% Annual Frin Ben	Total Annual Sal/Frin Ben	% OF TIME	% OF FTE	Monthly Rate	Mth	Salary Budget	Frin Ben Budget	Total Budget
9/30/2019 12/31/2019 1/1/2020 2/29/2020 3/1/2020 9/29/2020 9/30/2020 9/29/2021	A. PERSONNEL Sr. Physician Specialist 2233 5 William McFarland 2233 5 William McFarland 2233 5 William McFarland 2233 5 William McFarland	192,300 192,300 192,300 197,300	58,171 58,171 58,171 59,683	250,471 250,471 250,471 256,983	25% 25% 20% 20%	25% 25% 25% 20%	16,025 16,025 16,025 16,442	3.0 2.0 7.0 12.0	12,019 8,013 28,044 39,460	3,636 2,424 8,483 11,937	15,654 10,436 36,527 51,397
	TOTAL PERSONNEL:	774,200	234,196	1,008,396		0.95			87,535	26,479	114,014
	00101 SALARIES: 00103 MANDATORY FRINGE: TOTAL PERSONNEL:										87,535 26,479 114,014
	TOTAL DIRE	CT COST									114,014
	INDIRECT C	OST (12% c	of Total Dire	ect Cost)							13,682
TOTAL BUDGET											127,696

Research Subaward Agreement 11626sc between The Regents of the University of California and City and County of San Francisco

This Research Subaward Agreement ("Subaward") is executed by and between The Regents of the University of California, on behalf of its San Francisco campus, a corporation of the State of California, (hereinafter "UCSF") and City and County of San Francisco (hereinafter "Subrecipient").

WHEREAS, UCSF is the recipient of Award Number 1 NU2GGH002183-01-00 ("Award") from Centers for Disease Control ("CDC" or "Sponsor"), for the conduct of a program entitled "Targeted HIV/TB Strategic Information Technical Assistance for President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) Countries" ("Project") as detailed in the application previously submitted to the Sponsor; and

WHEREAS it is considered in the best interests of the Sponsor and UCSF for Subrecipient to participate in this Project;

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, UCSF and Subrecipient agree to a Subaward under this Award.

Article I – Scope of Work

Subrecipient shall perform those tasks described in Subrecipient's Scope of Work (Attachment A), which is incorporated herein and made a part of this agreement.

Article II – Project Management

George Rutherford is designated as UCSF's Principal Investigator, who is responsible for the overall conduct of the Project and is responsible for overall technical monitoring and guidance. Any significant changes in the performance of this Subaward as outlined in Subrecipient's proposal and Scope of Work require authorization by UCSF's Principal Investigator.

William McFarland is designated as Subrecipient's Principal Investigator who shall be responsible for the technical and administrative conduct of the Project in accordance with Attachment A. No substitution may be made of Subrecipient's Principal Investigator without prior written approval of UCSF and an amendment to this Subaward.

Article III – Period of Performance

The authorized period of performance is from **September 30, 2019** through **December 31, 2019**. The period of performance may be extended only by written amendment to this Subaward. UCSF may issue no-cost extensions to the period of performance unilaterally, except that Subrecipient shall retain the right to decline such an extension by notifying UCSF's Authorized Official within 30 days from receipt of the amendment. Unilateral acceptance of the amendment does not bypass internal approval processes of Subrecipient.

Article IV – Compensation

UCSF will reimburse Subrecipient on a cost-reimbursable basis for actual allowable costs in the performance of the work under this Subaward in the amount not to exceed **\$17,533** which is based on the budget incorporated herein and made part of this Subaward as Attachment B. Expenditures shall be in accordance with Attachment B, Sponsor's policies, and

the terms and conditions of this Subaward. This amount shall not be exceeded or carried forward without written authorization of UCSF's Principal Investigator and subsequent formal amendment to this Subaward. None of the funds obligated in this Subaward shall be used to pay the salary of an individual at a rate in excess of Executive Level II.

Article V – Method of Payment

Subrecipient shall submit monthly invoices in US Dollars to UCSF after incurring allowable costs. All invoices must provide a current and cumulative breakdown of costs by major cost category in accordance with Attachment B. All invoices shall be dated, numbered, and must include this Subaward number, **11626sc**. Invoices submitted without this information may delay payment. Invoices shall include certification that expenditures claimed represent actual allowable costs for committed effort and work performed under this Subaward. Subrecipient invoices shall be sent to the attention of:

University of California, San Francisco Campus (UCSF) Supply Chain Management - Accounts Payable Attn: Subcontracts Desk Box 0812 1855 Folsom Street, Suite 304 San Francisco, CA 94143-0812 Email: subcontract@ucsf.edu

For questions about invoicing, contact <u>scmap@ucsf.edu</u>. UCSF will make provisional payment on all invoices submitted in accordance with the terms of this Subaward. The final invoice marked "FINAL" must be submitted within forty-five (45) days after the final end date of this Subaward.

Unexpended funds, if any, shall be returned to UCSF with the final financial report. The closeout of this Subaward does not affect the right of UCSF or Sponsor to disallow costs and recover funds on the basis of a later audit or other review.

Article VI – Progress and Financial Reporting Requirements

Subrecipient shall furnish to UCSF any financial, technical, or performance reports and assistance reasonably requested by UCSF's Principal Investigator as required to meet UCSFs obligations under the Award. All reports required under the Award are due to UCSF **thirty (30) days** before the due date specified in the Award. Technical reports should include a summary statement of progress toward the achievement of the originally stated aims, a list of the positive and negative results which are considered to be significant by Subrecipient's Principal Investigator, and a list of any publications resulting from the Project, including planned publication. All such reports shall be submitted to UCSF's Principal Investigator.

Article VII – Audit and Records

a) Subrecipient shall maintain accurate records of all costs incurred in the performance of this work and agrees to allow representatives of UCSF, Sponsor, and/or the Comptroller General of the United States reasonable access to its records to verify the validity of expenses reimbursed under this Subaward. Subrecipient shall maintain financial records, supporting documents, and other records pertaining to this Subaward for a period as required by applicable laws and regulations. Notwithstanding the foregoing sentence, any records pertaining to audit, appeals, litigation, or claims arising out of performance of this Subaward shall be retained until such audits, appeals, litigation, or claims have been disposed of.

b) All research records, including but not limited to original data and primary data-yielding materials, secondarily derived tables and figures, and statistical tabulations and other summaries, pertinent to this Subaward shall be made available to UCSF upon its request and shall be retained by Subrecipient for a period as required by applicable laws and regulations. Notwithstanding, if any litigation, claim, or audit begins before the end of the retention period specified herein and the final action related to the litigation, claim, or audit is not taken before the end of that period, Subrecipient must retain all

records related to this Subaward that may be involved in the litigation, claim, or audit until all findings involving the records have been resolved and final action taken.

c) If any audit report reflects major shortcomings in Subrecipient's internal control systems, UCSF may impose more stringent prior approval requirements for certain types of expenditures and/or rebudgeting, and may require detailed supporting documentation for all claims for reimbursement until UCSF is satisfied that necessary corrective action has been, or will be taken.

d) UCSF, the Sponsor, the Comptroller General of the United States, and any of their duly authorized representatives shall have access at any reasonable mutually agreeable time after prior written notification to pertinent books, documents, papers, and records of Subrecipient in order to make audits, examinations, excerpts, and transcripts. In the event that any payment made to Subrecipient is determined on the basis of such audits to be unallowable, Subrecipient shall promptly refund the unallowable amount to UCSF upon demand.

Article VIII – Publicity and Publication

Neither party will use the name of the other party or its employees in any advertisement, press release, or other publicity without the prior written approval of the other party. Subrecipient understands that California Education Code Section 92000 provides that the name "University of California" is the property of the State of California and that no person shall use that name without the permission of The Regents of the University of California. Such permission may be granted by the Chancellor or his designee. UCSF has the right to acknowledge Subrecipient's participation in and support of the work performed under this Subaward in press releases, scientific publications, and other scientific communications.

Subrecipient shall be able to disclose the identity of the parties, the existence of the agreement, and the nature and scope of the research in accordance with its institutional policies, but will not use Sponsor's name or logo without UCSF obtaining written permission of Sponsor's Director of Communications or equivalent position. The previous sentence notwithstanding, publication of Project results shall acknowledge the Award made to UCSF from Sponsor.

Publications, journal articles, etc. produced under a CDC grant support project must bear an acknowledgment and disclaimer, as appropriate, for example:

"This publication (journal article, etc.) was supported by the Grant or Cooperative Agreement Number, 1 NU2GGH002183-01-00, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services."

When issuing statements, press releases, requests for proposals, bid solicitations, and other documents describing projects or programs funded in whole or in part with Federal money, all awardees receiving federal funds, including and not limited to

State and local governments and grantees of Federal research grants, shall clearly state:

- The percentage of the total costs of the program or project which will be financed with federal money,
- The dollar amount of federal funds for the project or program, and
- The percentage and dollar amount of the total costs of the project or program that will be financed by nongovernmental sources

Article IX – Intellectual Property

Copyright:

Subrecipient may assert copyright ownership on materials that it produces in the performance of the work of this Subaward. Subrecipient shall grant to UCSF a non-transferable, irrevocable, royalty-free, non-exclusive license to use, reproduce, prepare derivative works, perform, display, publish, or otherwise disseminate such copyrighted materials first

developed and delivered under this Subaward for non-commercial research, academic, and educational purposes, and as required to meet any obligations under the Award.

Pursuant to applicable grant regulations and the CDC's Public Access Policy, Subrecipient agrees to submit into the National Institutes of Health Manuscript Submission System (NIHMS) an electronic version of the final, peer-reviewed manuscript of any such work developed under this award upon acceptance for publication, to be made publicly available no later than twelve (12) months after the official date of publication. Also at the time of submission, Subrecipient and/or the Subrecipient's submitting author must specify the date the final manuscript will be publicly accessible through PubMed Central (PMC). Subrecipient and/or Subrecipient's submitting author must also post the manuscript through PMC within twelve (12) months of the publisher's official date of final publication; however, the author is strongly encouraged to make the subject manuscript available as soon as possible. The Subrecipient must obtain prior approval from UCSF for any exception to this provision.

The author's final, peer-reviewed manuscript is defined as the final version accepted for journal publication, and includes all modifications from the publishing peer review process, and all graphics and supplemental material associated with the article. Subrecipient and its submitting authors working under this award are responsible for ensuring that any publishing or copyright agreements concerning submitted articles reserve adequate rights to fully comply with this provision and the license reserved by the CDC. The manuscript will be hosted in both PMC and the CDC Stacks institutional repository system. In progress reports for this award, recipient must identify publications subject to the CDC Public Access Policy by using the applicable NIHMS identification number for up to three (3) months after the publication date and the PubMed Central identification number (PMCID) thereafter.

Patents and Inventions:

Subrecipient is subject to applicable regulations governing patents and inventions, including government-wide regulations issued by the Department of Commerce at 37 CFR 401, "Rights to Inventions made by Non-profit Organizations and Small Business Firms Under Government Grants, Contracts and Cooperative Agreements." Acceptance of Award funds obligates Subrecipient to comply with the standard patent rights clauses at 37 CFR 401.14.

Article X – Independent Contractor

Subrecipient and its employees, consultants, agents, or independent contractors will perform all services under this Subaward as independent contractors. Nothing in this Subaward will be deemed to create an employer-employee or principal-agent relationship between UCSF and Subrecipient's employees, consultants, agents, or independent contractors. Subrecipient and its employees, consultants, agents, and lower tier Subrecipients will not, by virtue of any services provided under this Subaward, be entitled to participate, as an employee or otherwise, in or under any employee benefit plan of UCSF or any other employment right or benefit available to or enjoyed by employees of UCSF.

Article XI – Indemnification

Each party shall be responsible for its negligent acts or omissions and the negligent acts or omissions of its employees, officers, or directors, to the extent allowed by law.

Article XII – Insurance

Subrecipient shall maintain at its expense, during the period of this Subaward, insurance or an equivalent form of self-insurance acceptable to UCSF in terms as follows:

a) Commercial Form General Liability (contractual liability included) with limits as follows:

Each Occurrence	\$1,000,000
Products, Completed Operations Aggregate	\$2,000,000
Personal and Advertising Injury	\$1,000,000

General Aggregate

\$2,000,000

b) If the above insurance is written on a claims-made form, it shall continue for three (3) years following termination of this Subaward. The insurance shall have a retroactive date of placement prior to or coinciding with the effective date of this Subaward.

c) Business Automobile Liability (Minimum Limits) for owned, scheduled, non-owned, or hired automobiles with combined single limit of not less than \$1,000,000 per occurrence

d) Workers' Compensation Coverage per statutory limits

e) The coverages referred to shall include The Regents of the University of California as an additional insured. Such a provision shall apply only in proportion to and to the extent of the negligent acts or omissions of Subrecipient, its officers, employees, and agents. Subrecipient, upon request, shall furnish UCSF with certificates of insurance evidencing compliance with all requirements. Certificates shall further provide for thirty (30) days (10 days for non-payment of premium) advance written notice to UCSF of any material modification, change, or cancellation of the above insurance coverages.

Article XIII – Suspension/Termination

In the event Sponsor suspends or terminates its award to UCSF, UCSF shall suspend or terminate this Subaward. Notification of suspension or termination by UCSF shall be provided to Subrecipient in writing as soon as practicable and shall state the effective date of such action.

Either party may terminate this Subaward upon thirty (30) days advance written notice to the other party. In the event of such termination, Subrecipient shall take all reasonable steps to minimize further costs, and shall be entitled to reimbursement for allowable costs and non-cancellable obligations incurred prior to the effective date of termination, except that in no event shall such reimbursement exceed the amount set forth in Article IV (Compensation). Unless otherwise agreed to by the parties, within thirty (30) days after the final end date, Subrecipient shall submit a final invoice to UCSF. The balance owed to Subrecipient will be paid contingent upon receipt of all final reports. The preceding sentence notwithstanding, UCSF will be unable to reimburse any expenses under suspension or termination unless and until Sponsor reimburses UCSF for such costs.

In the event of early termination, Subrecipient agrees to deliver such information and items which are either completed prior to the effective date of termination, or which Subrecipient can reasonably be expected to prepare and furnish to UCSF per the approved Scope of Work and the terms of this Subaward.

Article XIV – Notices

Notices required or permitted under this Subaward shall be directed to the Administrative Contact listed in Attachment E.

Article XV – Award Terms and Conditions

a) Unless sections specifically exclude subrecipients from coverage, Subrecipient is subject to and shall comply with the following terms and conditions, which are incorporated herein or by reference and made a part of this Subaward:

- 1) 2 CFR 200, "Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards";
- 2) 45 CFR 75, "Uniform Administrative Requirements, Costs Principles, and Audit Requirements for Health and Human Services (HHS) Awards";
- 3) The HHS Grants Policy Statement, including addenda in effect as of the beginning date of the budget period;

- 4) The Notice of Award;
- 5) Restrictions on the expenditure of federal funds by Congressional appropriations acts (to the extent those restrictions are pertinent to the award);

It is intended that the referenced provisions shall apply to Subrecipient in such manner as is necessary to reflect its position in relation to UCSF, to ensure its obligations to UCSF and to the United States Government, and to enable UCSF to meet its obligations under the Award.

b) In the event of a conflict between the Award and this Subaward, the terms and conditions of this Subaward shall govern.

Article XVI – Financial Conflict of Interest

The financial conflicts of interest policy of Subrecipient Institution will apply. By execution of this Subaward Agreement, Subrecipient Institution certifies that its policy complies with 42 CFR 50.

Subrecipient shall report any financial conflict of interest to UCSF's COI Representative by emailing coiac@ucsf.edu. Any financial conflicts of interest identified shall subsequently be reported to Sponsor. Such report shall be made before the expenditure of funds authorized in this Subaward Agreement and within 45 days of any subsequently identified financial conflict of interest.

Article XVII – Assurances/Certifications

By signing the Subaward Agreement, the authorized official of Subrecipient makes, to the best of his/her knowledge and belief, the Representations and Certifications in Attachment D.

Article XVIII – Governing Law

This Subaward is governed by the laws of the State of California.

Article XIX – Entire Subaward

This Subaward, including its attachments, states the entire agreement between the parties with respect to the subject matter of this Subaward and supersedes any previous or contemporaneous written or oral representations, statements, negotiations, or Subawards. Subrecipient acknowledges that it has not been induced to enter into this Subaward by any oral or written statements or representations not expressly provided in this Subaward.

Attachment A – Subrecipient Scope of Work Attachment B – Subrecipient Budget Attachment C – Award Attachment D – Representations and Certifications Attachment E – Contacts

IN WITNESS WHEREOF, the parties hereto have executed this Subaward on the month, day, and year specified below.

FOR: The Regents of the University of California

Philip DeBiase Philip DeBiase Associate Manager, Subcontracts Date:^{1/22/2020} FOR: City and County of San Francisco Tomas Aragon, Director of Population Health Division OBDB2B95DBC0442... Date: 01/10/2020 | 4:55 PM PST

Attachment A

Project Name: Burma Cooperative Agreement NU2GGH002183-01-00 San Francisco Department of Public Health (SFDPH) Scope of Work

1. Name of Contractor: San Francisco Department of Public Health (SFDPH).

2. Period of Performance: September 30, 2019 to December 31, 2019

3. Scope of Work: The SFDPH subcontractor, Dr. William McFarland, will support Myanmar project needs. As part of the scope of work, Dr. McFarland will provide technical assistance on HIV surveillance related activities and facilitate or co-facilitate in-country trainings and workshops. He will also be responsible for developing study and training materials and participate regularly on conference calls and meetings.

Attachment B

San Francisco Department of Public Health Subcontract Budget Period: 9/30/2019 - 12/31/2019 Budget Name: SIQHIL Burma

<u>A. Salaries and Wages</u> Personnel McFarland, William	Position Title Director of Surveillance	Current Salary \$192,300		# mos. 3	(A) Salary \$12,019	(B) Benefits \$3,636	Total \$15,654 \$0 \$0 \$0 \$0
Total Personnel			25%		\$12,019	\$3,636	\$15,654
Total Direct Costs Overhead at 12% Grand Total							\$15,654 <u>\$1,879</u> \$17,533

Project Name: Burma Cooperative Agreement NU2GGH002183-01-00 San Francisco Department of Public Health (SFDPH) **Budget Justification**

Salaries and Wages:

William McFarland, MD, PhD, MPH&TM, Director of Surveillance, Professor and Faculty Advisor, UCSF and Director of the Center for Public Health Research at SFDPH, will provide technical assistance on all surveillance planning and implementation activities in Myanmar, and lead in-country technical trainings/workshops. We request 25% (\$12,019) salary support for this position for 3 months.

Fringe Benefit:

The fringe benefit rate for this subcontract is calculated as follows:

	Salary Requested	% Benefit Rate	Total Fringe Benefits
McFarland, William	\$ 12,019	30.25%	\$ 3,636

Total Direct Costs

Indirect Cost Rates:

The indirect cost rate is 12% of total direct expenses and is in compliance with the bilateral agreement between UCSF and SFDPH.

Total: \$17,533

Total: \$15,654

Total: \$3,636

Total: \$1,879

Total: \$12,019

DocuSign Envelope ID: 89147180-DB8E-44BE-9906-1D67BF81159C ichment C

1. DATE ISSUED MM/DD/YYYY 1a. SUPERSEDES AWARD NOTICE dated except that any additions or restrictions previously imposed DEPARTMENT OF HEALTH AND HUMAN SERVICES remain in effect unless specifically rescinded **Centers for Disease Control and Prevention CDC Office of Financial Resources** 93.067 - Global AIDS 3. ASSISTANCE TYPE Cooperative Agreement 2939 Brandywine Road Atlanta, GA 30341 4. GRANT NO. 1 NU2GGH002183-01-00 5. TYPE OF AWARD Other 4a. FAIN NU2GGH002183 5a. ACTION TYPE New 6. PROJECT PERIOD NOTICE OF AWARD MM/DD/YYYY MM/DD/YYYY From 09/30/2019 Through 09/29/2024 AUTHORIZATION (Legislation/Regulations) 7. BUDGET PERIOD 42 USC 287b 31 USC 6305 42 CFR 63a MM/DD/YYYY MM/DD/YYYY From 09/30/2019 Through 09/29/2020

8. TITLE OF PROJECT (OR PROGRAM)

08/27/2019

Formerly

2. CFDA NO.

Targeted HIV/TB Strategic Information Technical Assistance for President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) Countries

9a. GRANTEE NAME AND ADDRESS	9b. GRANTEE PROJECT DIRECTOR	
Regents of the University of California, San Francisco, The	Dr. GEORGE WILLIAMS RUTHERFORD	
3333 California St	555 16th Street	
San Francisco, CA 94118-1981	Box 1224	
	Instittute for Global Health Sciences	
	SAN FRANCISCO, CA 94143-1224	
10a. GRANTEE AUTHORIZING OFFICIAL	10b. FEDERAL PROJECT OFFICER	
Ms. Magdalene Cho	Mrs. Priyanka Rathod	
3333 California Street, Ste 109	12 Corporate Boulevard, NE	
3333 California Street, Ste 109 Box 987	12 Corporate Boulevard, NE Atlanta, GA 30329	

		ALL	AMOUNTS ARE	SHOWN IN U	SD			
11. APP	ROVED BUDGET (Exclu	des Direct Assistance)		12. AWARD	COMPUTATION		-	
I Finar	ncial Assistance from the	Federal Awarding Agency Only		a. Amount o	of Federal Financial Assistance (from	item 11m)		724,500.00
II Total	project costs including g	rant funds and all other financial participation	1	b. Less Und	bligated Balance From Prior Budget	Periods		0.00
a.	Salaries and WageS		195,158.00		nulative Prior Award(s) This Budget P			0.00
	Eringo Donofito		00 405 00	d. AMOUN	OF FINANCIAL ASSISTANCE THI	S ACTION		724,500.00
b.	Fringe Benefits		69,495.00	13. Total Fee	leral Funds Awarded to Date for Pr	roject Period		724,500.00
с.	Total Personnel Co	sts	264,653.00		IENDED FUTURE SUPPORT			
d.	Equipment		0.00		he availability of funds and satisfacto	ry progress of the p	roject):	
e.	Supplies		6,325.00	YEAR	TOTAL DIRECT COSTS	YEAR	TOTAL	DIRECT COSTS
			122,372.00	a. 2		d. 5		
t.	Travel		122,372.00	b. 3		e. 6		
g.	Construction		0.00	c. 4		f. 7		
h.	Other		93,987.00	15. PROGRAM ALTERNATIVE	INCOME SHALL BE USED IN ACCORD WITH S:	ONE OF THE FOLLOWIN	IG	
i.	Contractual		143,434.00	a. b.	DEDUCTION ADDITIONAL COSTS			b
j.	TOTAL DIRECT C	osts	630,771.00	c. d. e.	MATCHING OTHER RESEARCH (Add / Deduct Option) OTHER (See REMARKS)			
k.	INDIRECT COSTS		93,729.00	40	·		L	
١.	TOTAL APPROVED B	UDGET	724,500.00	ON THE ABOVE	D IS BASED ON AN APPLICATION SUBMITTE TITLED PROJECT AND IS SUBJECT TO THE TI NCE IN THE FOLLOWING: The grant program legislation			
m.	Federal Share		724,500.00	b. c. d.	The grant program regulations. This award notice including terms and conditions Federal administrative requirements, cost princi			is grant.
n. Non-Federal Share 0.00				prevail. Accep	ere are conflicting or otherwise inconsistent p tance of the grant terms and conditions is ac he grant payment system.			
RE	MARKS (Other Terms	and Conditions Attached -		No)				

GRANTS MANAGEMENT OFFICIAL:

Randolph Williams 2920 Brandywine Rd Mailstop K75 Atlanta, GA 30341-5539 Phone: 770-488-8382

17.0BJ CLA	ASS 41.51	18a. VENDOR CODE	1946036493A6	18b. EIN	946036493	19. DUN	IS 094878337	20. CO	NG. DIST. 12
FY	-ACCOUNT NO.	DOCUM	ENT NO.		ADMINISTRATIVE CODE	A	MT ACTION FIN ASST	Α	PPROPRIATION
21. a.	9-93904SL	b. 19NU2GGH	00218319HQTB	с.	GH	d.	\$200,000.00	e.	75-19-0950
22. a.	9-93909D9	b. 19NU2GGH	0218319ABCO	с.	GH	d.	\$197,000.00	e.	75-19-1721-1031-001
23. a.	9-9390BHZ	b. 19NU2GGH	0218319VNCO	C.	GH	d.	\$30,000.00	e.	75-19-1822-1031-001

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 2	DATE ISSUED
	08/27/2019

GRANT NO. 1 NU2GGH002183-01-00

[FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	AMT ACTION FIN ASST	APPROPRIATION
[24.a. 9-9390BL2	b. 19NU2GGH002183WHCC	c. GH	d. \$297,500.00	e. 75-19-1822-1031-001

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

Regents Of The University Of California, San Francisco, The

1 NU2GGH002183-01-00

1. Terms and Conditions

2. Budget table

3. TR

4. CDC Budget guidelines

Funding Opportunity Announcement (FOA) Number: **GH19-1951** Award Number: GH002183 Award Type: Cooperative Agreement Applicable Regulations: 45 Code of Federal Regulations (CFR) Part 75, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for HHS Awards

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at https://www.cdc.gov/grants/federalregulationspolicies/index.html, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number GH19-1951, entitled, "Strategic Information Support Across Countries Under the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria and under the President's *Emergency Plan for AIDS Relief (PEPFAR)*", and application dated October 11, 2018, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of **\$** 5,000,000 is approved for the Year 01 budget period, which is September 30, 2019 through September 29, 2020. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

Available Funding(Component Funding):: Funding in the amount of \$724,500 in Financial Assistance (FA) is awarded on this NoA. The remainder of the budget period Approved Funding amount is subject to the availability of funds.

The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

Funding for this notice of award is approved, as follows:				
Component	Amount			
Quarter 1 Part 1	\$ 724,500			

Component	Amount
Quarter 1 Part 1	\$ 724,500

The following category/component(s) are approved but unfunded:				
Component	Amount			
Quarter 1 Part 2	\$ 400,000			
Quarter 2 Part 1	\$ 325,000			
Quarter 2 Part 2	\$ 325,000			
Quarter 3 Part 2	\$ 600,000			
Quarter 3 Part 2	\$ 373,000			
Quarter 4 Part 1	\$1,352,500			
Quarter 4 Part 2	\$ 900,000			
Total	\$ 4,275,500			

Working Capital Method: Recipients are authorized to utilize a working capital method when drawing down funds under this award. The method authorizes recipients to draw down funds to cover obligations to be reconciled and the funds dispersed within 30 days of the date of the draw down

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

Objective/Technical Review Statement Response Requirement: The review comments on the strengths and weaknesses of the proposal are provided as part of this award. A response to the weaknesses in these statements must be submitted to and approved, in writing, by the Grants Management Specialist/Grants Management Officer (GMS/GMO) noted in the CDC Staff Contacts section of this NoA, no later than 30 days from the budget period start date. Failure to submit the required information by the due date, November 4, 2019, will cause delay in programmatic progress and will adversely affect the future funding of this project.

Budget Revision Requirement: By **November 4, 2019** the recipient must submit a revised budget with a narrative justification. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date.

<u>Additional info is requested for the following budget categories:</u> Ensure sub recipients budget is prepared per CDC Budget guidelines.

- Salaries- TBD Positions are listed. Provide the names once TBD positions are filled. Ensure LOE is allocated accordingly between this and all other federal awards. Combined LOE should not exceed 100%. HQ based staff salary cost seems high and not reasonable or sustainable.
 - Too many HQ staff are listed. Ensure there is no duplication of effort by HQ staff and incountry based staff. Revised budget is request.
 - Some of the salary increases are as high as 26% from prior year to this year. These
 increments are excessive and not reasonable. Excessive salary will be restricted if not
 addressed in the revised budget.
 - Staff salaries should also be consistent in all CDC awards. Some of the staff salaries listed are different from what is listed for the same staff in other current CDC awards for the same budget period.

Position Title	Name	Prior Yr	This award	Increase AMT	% Increase
Deputy	Young, Kelly H	\$182,747	\$189,600	\$6,853	4%
Core Lead	Geng, Elvin		\$189,600		?
Director of Strategic Information	Waruiru, Wanjiru	\$102,467	\$121,048	\$18,581	18%
Director of M&E	Myrick, Roger K	\$187,000	\$189,600	\$2,600	1%
Sr. Technical Advisor	Smith, Nathan M	\$137,993	\$147,428	\$9,435	7%
Sr. Technical Advisor	Weissglas, Fitti Guido	\$113,301	\$142,014	\$28,713	25%
Core Lead	Karen White Horn,	\$0	\$189,600		?
Grant Manager	Atour Malko		\$117,639	\$117,639	?
Project Analyst	Rogers, Celeste A	\$90,248	\$96,028	\$5,780	6%
Global Programs Operations	Drake, Jane E	\$0	\$163,571	\$163,571	
Director of Grants Management	Frank, Heidi Rachel	\$136,913	\$172,604	\$35,691	26%
** Director of Staffing	Usma Khan,		\$191,290		?
**Operations Coordinator	Matthew Greenway		\$90,994		?
** some of these are admin pos	itions - should be cove	red by indire	ct cost		

- Some of the HQ position listed in the award are administrative positions that covered by UCSF Indirect cost. These should not be billed directly to the award since they should be covered by UCSF Indirect cost charged to this award. UCSF must ensure that costs are consistently charged as either indirect or direct costs, but may not be double charged or inconsistently charged as both. Too many directors and managers are listed.. not necessary or reasonable to have these many positions.
 - Core Leads
 - o Technical Directors
 - o Analysts
 - Global Programs Operations
 - Director of Grants Management
 - Grant Manager
 - Some of these positions appear duplicated with other CDC awards or should not even be listed.
 - UCSF must ensure there is no budget overlap between this and other UCSF awards.
 - UCSF All salary proposed should be reasonable, allowable, necessary and allocable.
- **Benefits**: \$884,284- Ensure proposed benefits is consistent with similar organization providing similar activities in the country. Ensure this is provided in accordance with CDC budget guidelines.
- **Travel:** \$224,420- Ensure proposed travel is reasonable and necessary. Provide information who is traveling, where and when. Ensure this is provided in accordance with CDC budget guidelines. Revised budget requested.
- **Supplies:** Detail listing and description is needed for all items listed in the supplies budget category. Information provided is not sufficient.
- Other- Trainings, meeting and workshops cost seems excessive. Detail listing of proposed training, workshops and meetings and associated cost is needed. Training/workshops/meetings must have a budget, locations, number of attendants and related costs. Information provided is not sufficient. Ensure to provide this information per CDC budget guidelines
 - Provide listing of location of training events when and who are the participants and how many?
 - Consider combining some of the proposed training/meeting events which would be cost effective.
- **Contractual cost– Sub- recipients /Sub awards Costs:** University of California, San Francisco (UCSF) is responsible for monitoring Sub recipients.
 - UCSF must ensure that sub recipients are in compliance with grant rules and regulations.
 - UCSF must also ensure that Sub recipients have adequate internal controls and systems in place to ensure that awards funds are used appropriately to avoid fraud, waste and abuse.
 - Sub recipients must establish and maintain effective internal control over Federal awards to ensure compliance with Federal statutes, regulations, and the terms and conditions of the Federal award.
 - UCSF must ensure costs proposed by sub-recipients are necessary, allowable, reasonable and allocable.
 - UCSF should ensure detail budget information is provided for proposed sub recipients in accordance with CDC Budget Guidelines.in accordance with CDC Budget guidelines. Ensure to provide Budget is excel format as well.

Program Income: Any program income generated under this grant or cooperative agreement will be used in accordance with the *Addition* alternative.

<u>Addition alternative</u>: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

Note: The disposition of program income must have written prior approval from the GMO.

FUNDING RESTRICTIONS AND LIMITATIONS

Human Subjects Restriction(s): In addition to service provision, this application includes support for potential data collection from persons, personal records, or for laboratory specimen collection and testing that may result in public dissemination. Of the total approved budget **\$800,000**, shall be restricted until protocols describing the activities below have been submitted to CDC DGHT-Atlanta for scientific/technical review and review of institutional human subjects protection considerations.

A. Restriction ID Number: HQ-19-002183-01

Restricted Activity: Adapting surveillance methods and designing innovative mortality survey methodologies Page(s): 11

Restriction Amount: \$100,000 Cost Category: Salaries

B. Restriction ID Number: **HQ-19-002183-02** Restricted Activity: Adapting surveillance methods and designing innovative mortality survey

methodologies

Page(s): 11 Restriction Amount: \$100,000 Cost Category: Travel

- C. Restriction ID Number: HQ-19-002183-03
 Restricted Activity: Design Surveillance methodologies based on routine program data system Page(s): 12
 Restriction Amount: \$200,000
 Cost Category: Salaries
- D. Restriction ID Number: HQ-19-002183-04
 Restricted Activity: Provide support for analysis, writing, dissemination and use of results Page(s): 12
 Restriction Amount: \$100,000
 Cost Category: Contractual
- E. Restriction ID Number: HQ-19-002183-05
 Restricted Activity: Evaluation to analyze program data quality assessment results over time, interviews with community and site staff
 Page(s): 18
 Restriction Amount: \$100,000
 Cost Category: Contractual
- F. Restriction ID Number: HQ-19-002183-06 Restricted Activity: Target support for developing statistical methods for HIV and TB data analysis and use

Page(s): 13 Restriction Amount: \$200,000 Cost Category: Contractual

All funding restrictions placed on potential data collection activities involving human subjects must be resolved no later than the end of this budget year. Data collection protocols required to release funding restrictions placed on potential data collection activities involving human subjects must be submitted to the DGHT Science Integrity Branch for review within 6 months of receiving the Notice of Award. Exceptions to these deadlines will need to be submitted in writing to the Office of Financial Resources (OFR) Grants Management Officer. If any of the restricted activities have received local IRB approval, an IRB-exempt determination, or an institutional non-research determination please submit the approval documentation with the protocol to the **Headquarters** CDC DGHT Office.

When all necessary CDC approvals have been obtained for a restricted activity, please submit a copy of the approval(s) along with a release of Human Subjects Data Collection Restriction Release Request Form to your OFR Grants Management Specialist via email.

Note 1: If funds for preparatory activities (e.g., protocol development, training, equipment, reagents, and site preparation) were not included in the application, these funds may be provided prior to protocol approval. To request funds for preparatory activities please submit a narrative describing the activities along with a release of Human Subjects Data Collection Restriction Release Request Form to your OFR Grants Management Specialist via email.

Note 2: If the restricted activity is a part of routine clinic or program operations, or laboratory quality assurance that will not result in public dissemination, please submit a narrative justification along with a release of Human Subjects Data Collection Restriction Release Request Form and country approval to your OFR Grants Management Specialist via email. Protocol approval is not required for these activities.

Note 3: Restricted funds shall not be withdrawn until approval is received and the restrictions have been lifted by an amended notice of award. Conducting any restricted activities without receiving CDC approval will result in enforcement action, which may require repayment of expended funds.

Note 4: With regard to scientific conference attendance, as stated in the Notice of Funding Opportunity, "IPs with accepted oral posters or oral abstracts for presentations that give clear attribution to PEPFAR may be authorized to use PEPFAR funds for travel providing that funds are available for travel. Funds for travel must be drawn from an existing agreement with the IP and not from PEPFAR country program management and operations budget. IPs must obtain prior approval from their respective Project Officer for participation and on availability and use of funds." Please note that use of cooperative agreement funds to attend scientific conferences by non-presenters and non-oral poster presenters is not authorized, except by Partner Government Officials with approval of the PEPFAR Deputy Principals through the process outlined in the Notice of Funding Opportunity.

To obtain the Human Subjects Data Collection Restriction Release Request Form, or for more information on releasing human subjects data collection restrictions, contact the **Headquarters** CDC DGHT Office.

Indirect Costs: Indirect costs are approved based on the Indirect Cost Rate Agreement dated November 27, 2017, which calculates indirect costs as follows, a Predetermined rate is approved at a rate of 26 % of the base, which includes, Modified total direct Costs, consisting of all salaries and wages, fringe benefits, materials, supplies, services, travel and subgrants and subcontracts up to the first \$25,000 of each subgrants and subcontracts. Modified Total direct costs shall exclude equipment, capital

expenditures, charges for patient care, student tuition remission, rental costs of off-site facilities, scholarships, fellowships as well as the portion of each subgrant and subcontract in excess of \$25,000.

The effective dates of this indirect cost rate are from 07/01/2016 to 6/30/2021

Foreign Taxes: Pursuant to applicable grant regulations, foreign taxes charged for the purchase of goods or services that a non-federal entity is legally required to pay in country are an allowable expense under federal awards. For purposes of this term, foreign taxes include value-added taxes (VAT), customs duties, and other similar charges levied on any transaction financed by HHS/CDC award funds in furtherance of program activities and objectives as set forth in the funding agreement, which may include the purchase, import, use or re-export of goods or services.

The determination of whether such foreign taxes are an allowable expense will depend on whether an exemption or effective reimbursement mechanism exists in country. Effective reimbursement is defined as a reimbursement mechanism that provides for no less than substantial reimbursement of USG funds. Generally such exemptions or rights to reimbursement are set forth in bilateral or other legal agreements between the United States Government (USG) and the host country.

1. Countries where an exemption or right to reimbursement exists:

In countries where a bilateral or other legal agreement sets forth an exemption, the recipient must take advantage of the exemption and may not pay taxes with award funds. If, however, the host country implements the exemption through a reimbursement mechanism, the recipient may pay the taxes with award funds but must request and receive the reimbursement, as those expenses are deemed an unallowable expense under the award. If the reimbursement mechanism is used, recipients should consult with the CDC project officer and the CDC grants management specialist to determine how the reimbursed funds should be handled. If reimbursement is requested but not received from the host country despite significant effort, so long as recipient provides sufficient documentation showing efforts to seek reimbursement to the CDC grants management specialist, the foreign tax payment will be an allowable expense.

- 2. <u>Countries where no exemption and/or no right to reimbursement exist</u>: In countries where a) there is no bilateral or other legal agreement in force setting forth either an exemption or a right to reimbursement, b) a bilateral or other legal agreement is in force but does not provide for an exemption or a right to reimbursement, the recipient may pay foreign taxes with award funds. Such payments would be deemed allowable expenses.
- 3. <u>Countries where a specific bilateral agreement between the US and the ost country (e.g., 1951 Bilateral Agreement between the US and the UK applicable to former UK territories; 1989 bilateral between the US and Swaziland) applies (Bahamas, India, Kenya, Suriname, Swaziland, Trinidad and Tobago, and Zambia)</u>:

Consistent with the bilateral agreement, this Notice of Grant Award represents the implementing agreement required by the bilateral agreement for tax purposes. Pursuant to the specific bilateral agreement in force, the host country has agreed that USG funds (e.g., HHS/CDC funds, PEPFAR funds) provided to and utilized by recipient, as it carries out the program activities and objectives set forth in this implementing agreement, shall be free from taxes imposed under laws in effect in the host country. These tax exemptions on USG funds include, but are not limited to, the following:

a. Taxes, customs duties, and other similar charges levied on any transaction financed by HHS/CDC award funds in furtherance of program activities and objectives as set forth in this agreement, which may include the purchase, import, use or re-export of goods or services, including value-added taxes (VAT). Goods include, but are not limited to, commodities, equipment and supplies, including automobiles, which have been imported for the purpose of the funded program activities and objectives.

b. Taxes of a non-Resident organization on income allowed by HHS/CDC to be derived from HHS/CDC funding of program activities and objectives set forth in this agreement.

c. Taxation on personal income paid from HHS/CDC funds to employees of Recipient who

pay taxes on their income to the United States Government; and

d. Should any conflict or disagreement about the above exemptions arise, Recipient agrees to promptly notify CDC (project officer or grants management officer) to work to resolve such matters, guided by the principle that the funding furnished by HHS/CDC is free from taxation.

Prostitution and Sex Trafficking (Items 1 through 6):

- 1. Consistent with Section 7631(e) of the U.S. Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003, 22 USC §§ 7601 et seq. ("the Leadership Act"), the U.S. Government is opposed to prostitution and related activities, which are inherently harmful and dehumanizing, and contribute to the phenomenon of trafficking in persons. None of the funds made available under this agreement may be used to promote or advocate the legalization or practice of prostitution or sex trafficking. Nothing in the preceding sentence shall be construed to preclude the provision to individuals of palliative care, treatment, or post-exposure pharmaceutical prophylaxis, and necessary pharmaceuticals and commodities, including test kits, condoms, and, when proven effective, microbicides.
- 2. Additionally, consistent with Section 7631(f) of the Leadership Act, a prime recipient that is a non-U.S. nongovernmental organization acknowledges that, by accepting this award, it agrees that it is opposed to the practices of prostitution and sex trafficking because of the psychological and physical risks they pose for women, men, and children.
- 3. Contractors and subcontractors are exempt from the above requirements if the contract or subcontract is for commercial items and services as defined in FAR 2.101, such as pharmaceuticals, medical supplies, logistics support, data management, and freight forwarding.
- 4. Notwithstanding the contract exemption above, not exempt from these provisions are recipients, subrecipients, contractors, and subcontractors that implement HIV/AIDS programs under this assistance award, any subaward, or procurement contract or subcontract by:
 - i. Providing supplies or services directly to the final populations receiving such supplies or services in host countries;
 - Providing technical assistance and training directly to host country individuals or entities on the provision of supplies or services to the final populations receiving such supplies and services; or
 - Providing the types of services listed in FAR 37.203(b)(1)-(6) that involve giving advice about substantive policies of a recipient, giving advice regarding the activities referenced in (i) and (ii), or making decisions or functioning in a recipient's chain of command (e.g., providing managerial or supervisory services approving financial transactions, personnel actions).
- 5. Subrecipients
 - i. Prime recipient shall insert the following provision in subawards or subcontracts: "None of the funds made available under this agreement may be used to promote or advocate the legalization or practice of prostitution or sex trafficking. Nothing in the preceding sentence shall be construed to preclude the provision to individuals of palliative care, treatment, or post-exposure pharmaceutical prophylaxis, and necessary pharmaceuticals and commodities, including test kits, condoms, and, when proven effective, microbicides."
 - ii. Prime recipients shall insert the following provision in subawards or subcontracts subject to Section 7631(f) (i.e., those to non-U.S. nongovernmental organizations): "By accepting this award, the subrecipient/ subcontractor agrees that it is opposed to the practices of prostitution and sex trafficking because of the psychological and physical risks they pose for women, men, and children."
- 6. The following definitions apply for purposes of the above provisions:
 - i. "Commercial sex act" means any sex act on account of which anything of value is given to or received by any person.
 - ii. "Prostitution" means procuring or providing any commercial sex act and the "practice of prostitution" has the same meaning.
 - iii. "Sex trafficking" means the recruitment, harboring, transportation, provision, or obtaining of a

person for the purpose of a commercial sex act. 22 U.S.C. 7102(9).

This provision includes express terms and conditions of the award and any violation of it shall be grounds for unilateral termination of the award by (HHS OPDIV) prior to the end of its term.

Any enforcement of this provision is subject to courts' orders in Alliance for Open Society International v. USAID (See, e.g., S.D.N.Y. 05 Civ. 8209, Orders filed on January 30, 2015 and June 6, 2017, granting permanent injunction).

Special Provision for HHS Protecting Life in Global Health Assistance is applicable to this award. In accordance with the United States *Protecting Life in Global Health Assistance* policy, a non-governmental organization (NGO) recipient of this award acknowledges that foreign NGOs that receive funds provided through this award, either as a prime recipient or subrecipient, are strictly prohibited, regardless of the source of funds, from performing abortions as a method of family planning or engaging in any activity that promotes abortion as a method of family planning, or to provide financial support to any other foreign non-governmental organization that conducts such activities. The link to the full text is at: https://www.cdc.gov/grants/federal-regulations-policies/index.html

REPORTING REQUIREMENTS

Reporting Requirements are included in the CDC General Terms and Conditions https://www.cdc.gov/grants/federalregulationspolicies/index.html.

Performance Progress and Monitoring: Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132**, "**Performance Progress and Monitoring Report**", **Expiration Date 8/31/2019** (or . The components of the PPMR are available for download at: https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html .

Reporting of Foreign Taxes: The U.S. Department of State requires that agencies collect and report information on the amount of taxes assessed, reimbursed and not reimbursed by a foreign government against commodities financed with funds appropriated by the U.S. Department of State, Foreign Operations and Related Programs Appropriations Act (SFOAA) of 2011 (United States foreign assistance funds). Outlined below are the specifics of this requirement:

- a. Annual Report. The recipient must submit a report on or before November 16 for each foreign country on the amount of foreign taxes charged, as of September 30 of the same year, by a foreign government on commodity purchase transactions valued at \$500 USD or more financed with United States foreign assistance funds under this grant during the prior United States fiscal year (October 1 September 30), and the amount reimbursed and unreimbursed by the foreign government. [Reports are required even if the recipient did not pay any taxes during the reporting period.]
- Quarterly Report. The recipient must quarterly submit a report on the amount of foreign taxes charged by a foreign government on commodity purchase transactions valued at \$500 USD or more financed with United States foreign assistance funds under this grant. This report shall be submitted no later than two weeks following the end of each quarter: April 15, July 15, October 15 and January 15.
- c. Terms: For purposes of this clause:
 - i. Commodity means any material, article, supplies, goods, or equipment;
 - ii. Foreign government includes any foreign government entity;
 - iii. Foreign taxes means value-added taxes and custom duties asses by a foreign government on a commodity. It does not include foreign sales taxes.
- d. Where: Submit the reports to the Director and Deputy Director of the CDC office in the country(ies) in which you are carrying out the activities associated with this cooperative

agreement. In countries where there is no CDC office, send reports to <u>VATreporting@cdc.gov</u>.

- e. Contents of Reports. The reports must contain:
 - i. recipient name;
 - ii. contact name with phone, fax, and e-mail;
 - iii. agreement number(s) if reporting by agreement(s);
 - iv. reporting period;
 - v. amount of foreign taxes assessed by each foreign government;
 - vi. amount of any foreign taxes reimburse by each foreign government;
 - vii. amount of foreign taxes unreimbursed by each foreign government.
- f. Sub-agreements. The recipient must include this reporting requirement in all applicable subgrants and other sub-agreements.

Required Disclosures for Federal Awardee Performance and Integrity Information System

(FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations of federal criminal law involving fraud, bribery, or gratuity violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services **Francis Muriithi**, Grants Management Specialist Centers for Disease Control and Prevention Global Health Services Branch 2939 Flowers Road, MS: TV-1 Atlanta, Georgia 30341 Fax: (770) 488-2688 (Include "Mandatory Grant Disclosures" in subject line) Email: IFD4@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services Office of the Inspector General ATTN: Mandatory Grant Disclosures, Intake Coordinator 330 Independence Avenue, SW Cohen Building, Room 5527 Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or Email: <u>MandatoryGranteeDisclosures@oig.hhs.gov</u>

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC

must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PROGRAM OR FUNDING GENERAL REQUIREMENTS

HIV Program Review Panel Requirement: All written materials, audiovisual materials, pictorials, questionnaires, survey instruments, websites, educational curricula and other relevant program materials must be reviewed and approved by an established program review panel. A list of reviewed materials and approval dates must be submitted to the CDC Grants Management Specialist identified in the CDC Roles and Responsibilities section of this NoA.

PEPFAR Branding: All PEPFAR-funded programs or activities must adhere to PEPFAR branding guidance, which includes guidance on the use of the PEPFAR logo and/or written attribution to PEPFAR. PEPFAR branding guidance can be found at http://www.pepfar.gov/reports/guidance/branding/index.htm

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to <u>hhstips@oig.hhs.gov</u> or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "**P** Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Document Number:	Comment
19NU2GGH00218319ABCO	Burma
19NU2GGH00218319VNCO	Vietnam
19NU2GGH00218319WHCC	Caribbean
19NU2GGH00218319HQTB	ТВ

Exchange Rate: All requests for funds contained in the budget, shall be stated in U.S. dollars. Once an award is made, CDC may not compensate foreign recipients for currency exchange fluctuations through the issuance of supplemental awards.

PROGRAM OR FUNDING SPECIFIC CLOSEOUT REQUIREMENTS

The Closeout Requirements are included in the General Terms and Conditions https://www.cdc.gov/grants/federalregulationspolicies/index.html

Final Performance Progress and Evaluation Report: This report should include the information specified in the NOFO and is submitted 90 days following the end of the period of performance via <u>www.grantsolutions.gov</u>. At a minimum, the report will include the following:

- Statement of progress made toward the achievement of originally stated aims.
- Description of results (positive or negative) considered significant.
- List of publications resulting from the project, with plans, if any, for further publication.

Additional guidance may be provided by the GMS and found at: https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html

CDC Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

GMS Contact:

Francis Muriithi, Grants Management Specialist Centers for Disease Control and Prevention Office of Grants Services Global Health Services Branch 2920 Brandywine Road, Mailstop: K-75 Atlanta, GA 30341 Email: ifd4@cdc.gov

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

Programmatic Contact:

Priyanka Rathoda , Project Officer Centers for Disease Control and Prevention Division of Global HIV/AIDS Phone: 404-718-5243 Email: wnv9@cdc.gov

Grants Management Officer: The GMO is the federal official responsible for the business and other nonprogrammatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

GMOContact:

Randolph Williams - Grants Management Officer Centers for Disease Control and Prevention Office of Grants Services |Global Health Services Branch 2939 Flowers Rd Atlanta, Ga 30341 Atlanta, GA 30341-4146 Telephone: (770) 488- 8382 Email: Gur2@cdc.gov

GRANTEE:	The Regents of the University of California, San Francisco		
Award Number:	NU2GGH002183		

	Recipient				
	Requested Funding	Approved Budget	Available New	Approved Future	
Budget Category	Amount	Period Ceiling	Funding	Funding	Available funding
Personnel	\$1,814,937	\$1,046,408	\$195,158	\$851,250	\$195,158
Fringe Benefits	\$884,284	\$719,495	\$69,495	\$650,000	\$69,495
Travel	\$224,420	\$222,372	\$122,372	\$100,000	\$122,372
Equipment	\$0	\$0	\$0	\$0	\$0
Supplies	\$15,600	\$131,325	\$6,325	\$125,000	\$6,325
Contractual	\$643,962	\$1,592,684	\$143,434	\$1,449,250	\$143,434
Alterations and Renovations		\$0	\$0	\$0	\$0
Other	\$241,862	\$968,987	\$93,987	\$875,000	\$93,987
TOTAL Direct Charges	\$3,825,065	\$4,681,271	\$630,771	\$4,050,500	\$630,771
Indirect Charges	\$1,174,935	\$318,729	\$93,729	\$225,000	\$93,729
TOTALS	\$5,000,000	\$5,000,000	\$724,500	\$4,275,500	\$724,500

Table 2 Country Breakdown of Available Funding						
Budget Category	TB Branch	CDC Vietnam	CDC Burma	CDC Caribbean		
Salary and Wages	\$40,000	\$6,000	\$59,158	\$90,000		
Fringe Benefits	\$10,000	\$2,500	\$20,495	\$36,500		
Travel	\$75,000	\$5,225	\$22,147	\$20,000		
Equipment	\$0	\$0	\$0	\$0		
Supplies	\$0	\$125	\$600	\$5,600		
Contractual	\$0	\$7,750	\$56,034	\$79,650		
Construction	\$0	\$0	\$0	\$0		
Other	\$75,000	\$2,150	\$2,037	\$14,800		
Total Direct Charges	\$200,000	\$23,750	\$160,471	\$246,550		
Indirect Costs	\$0	\$6,250	\$36,529	\$50,950		
Grand Total	\$200,000	\$30,000	\$197,000	\$297,500		

Table 3 Budget Period COP Funding Plan by Country/Branch				
Country	Approved Ceiling	Funding Provided	Remaining	
Burma	\$788,000	\$197,000	\$591,000	
CRO	\$1,500,000	\$297,500	\$1,202,500	
CID	\$150,000	\$0	\$150,000	
Mozambique	\$750,000	\$0	\$750,000	
Rwanda	\$300,000	\$0	\$300,000	
Tanzania	\$500,000	\$0	\$500,000	
TB Branch	\$200,000	\$200,000	\$0	
Vietnam	\$119,098	\$30,000	\$89,098	
Total	\$4,307,098	\$724,500	\$3,582,598	





FY19 New Award Field Office Memo

To: Center for Global Health, Office of the Director, Division of Global HIV and Tuberculosis, Program Budget and Extramural Management Branch (PBEMB)

From: DGHT / MEDAB

Date: 05/29/2019

Re: Notice of Funding Opportunity GH19-1951, *Targeted HIV/TB Strategic Information Technical Assistance for President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) Countries.*

The purpose of this memorandum is to provide feedback on the proposal submitted by *The Regents of the University of California, San Francisco* in response to Notice of Funding Opportunity GH19-1951.

The DGHT/ HQ- *Monitoring and Evaluation and Data Analysis Branch* (MEDAB) has reviewed the Summary Statements from the Objective Review Panel and the proposal from *The Regents of the University of California, San Francisco.*

DGHT/HQ/MEDAB provides the following information on this application:

Are there any special conditions for the award, including budgetary restrictions? \Box Yes \boxtimes No If yes, please indicate conditions or restrictions in the budgetary and/or recommendations section below.

Is a response to weaknesses by the recipient required to be in the Notice of Award? \boxtimes Yes \square No

Are there potential human subject research activities? \boxtimes Yes \square No If yes, please indicate conditions or restrictions in the budgetary and/or recommendations section below.

Is this award categorically excluded from the environmental health impact study requirement based on the health designation of the activities? \boxtimes Yes \square No If no, contact your PBEMB Extramural Specialist for further direction.

Brief Summary of Application based on ORP Summary Statement

Include only those comments from the ORP that are relevant to the award.

Strengths of Application:

- The activities listed in the application support the strategic information goals for CDC in this next phase of PEPFAR to reach epidemic control.(Page 3-15)
- The partners for collaboration are appropriate (APHL and Imperial College) to provide technical assistance for enhancing strategic information activities linked to lab data and for developing innovative statistical methodologies.
- The technical expertise of the staffing is appropriate to cover the technical areas with exceptions listed below.

Weaknesses of Application (if response is required specify action to be taken by recipient):



- The staffing budget and IDC is vastly higher to budget allotted to travel. IDC off-campus are very low compared to IDC of on –campus.
- Several staff are country leads in countries that have specific cooperative agreements with UCSF and should not be covered 100% by this HQ cooperative agreement (Kenya, Namibia and South Africa, Uganda).
- Scopes of work will need to be revised and modified to country level activities once funded.

Recommended Actions for Weaknesses of Application:

- Please revise staffing, IDC, travel budgets to reflect on the ground technical assistance from all the staff listed.
- Please revise funding for country leads where cooperative agreements currently exist.
- Once funded, please develop targeted scopes of work for each country.

Programmatic Budgetary Comments

Note: Programmatic budget restrictions, concerns, and comments should be addressed prior to the award being made. This will take place during the OGS Budget Discussion.

Marked up Budget Certification (select one)

□ I certify that I support the recipient's proposed categorical budget submitted in this application as it relates to the technical aspects of the project. No changes are required and no restrictions are recommended.

⊠ I wish to make the following comments/changes to the recipient's proposed categorical budget:

(Please use bullets and reference your comments with page numbers from the application. You may also provide handwritten comments on the proposed budget to support your comments)

- Please revise staffing, IDC, travel budgets to reflect on the ground technical assistance from all the staff listed.
- Please revise funding for country leads where cooperative agreements currently exist.

Recommendations (include any special conditions, but do not put potential HR/IRB restrictions/conditions in this section):

Indicate programmatic restrictions in table below (if applicable): Do not put potential HR/IRB restrictions/conditions in this section):

PLEASE NOTE BEFORE COMPLETING RESTRICTIONS:

- Recipients are not always funded at the level of the Year1 ceiling at the start of the award, generally due to delays in CDC's receipt of funds. As such, **do not penalize recipients for not completing unfunded activities.**
- When possible, the response to TR should be used as a management tool, as

Object Classification	Restriction Amount	
Salaries	\$	Click here to enter text.
Fringe Benefits	\$	Click here to enter text.
Consultants	\$	Click here to enter text.
Equipment	\$	Click here to enter text.
Supplies	\$	Click here to enter text.
Travel	\$	Click here to enter text.
Other	\$	Click here to enter text.



opposed to restricting funds. **Funds** should only be restricted when absolutely necessary.

• Only include programmatic restrictions that should be put in place for the funding components that will be awarded at this time. If future restrictions are needed, they can be added once future funding components are awarded.

Contractual	\$ Click here to enter text.
Direct Costs	\$ Click here to enter text.
Indirect Costs	\$ Click here to enter text.
Total	\$ Click here to enter text.

Restriction Justification: (*Must be completed if restrictions are identified above*, including any special conditions)

Click here to enter text.

Potential Human Subjects Data Collection Activities

This section captures the Country Office's technical review and recommendations for potential human subject/data collection activities. CDC DGHT Science Integrity Branch will consider these comments/recommendations when reviewing this application. The only human subjects data collection restrictions that should be included in the NOA are those listed in the official memo from the DGHT Science Integrity Branch.

Does the application describe data collection activities potentially involving human subjects? The following are examples of activities that may constitute human subjects data collection activities:

🗆 Yes 🛛 No	Abstraction	of data from	patient medica	l records

🗆 Yes 🛛 No	Laboratory analysis of biological specimens (screening for STIs, HIV drug resistence testing, etc.)
------------	---

- \Box Yes \boxtimes No Interviews with patients, family members, physicians
- \boxtimes Yes \square No Community surveys or national surveys
- \Box Yes \boxtimes No \qquad Administration of individual questionnaires
- \Box Yes \boxtimes No Focus group discussions
- \Box Yes \boxtimes No Public health or targeted evaluations

If the application includes any of these activities, a portion of funding should be restricted pending review of activities potentially involving human subjects at CDC and should be outlined in Table I below. *Specify the funding amount to be restricted as it relates to the specific activity potentially involving human subjects in order to avoid overall % restriction.*

Note: If the funding application includes human subject data collection activities that <u>have received the</u> <u>necessary approvals</u> (e.g., CGH project determination approval or CDC IRB approval) please denote these activities below in Table II.

Table I. Proposed Potential Human Subjects Data Collection Restrictions

Activity Description (Type of Activity/Study Population)	Page(s)	Proposed Restriction	Cost	Comments
--	---------	----------------------	------	----------







		Amount ^{1 2}	Category ³	
1.Provide support for adapting surveillance methods and designing innovative mortality survey methodologies	11	\$200,000.00	Salaries and Wages, Travel, IDC	
2. Design surveillance methodologies based on routine program data systems	12	\$50,000.00	Salaries and Wages, Travel, IDC	
3.		\$		
4.		\$		
5		\$		

Table II. Human Subjects Data Collection Activities Already Approved by CDC⁴

Activity Description (Type of Activity/Study Population)	Page(s)	Attached CDC Protocol Approval	Comments
1.			
2.			
3			
4.			
5			

Recipients engaged in research should be notified that they may need to apply to the U.S. Office for Human Research Protections (OHRP) for a Federal-Wide Assurance (FWA). An FWA is a pledge by an institution that they will adhere to ethical principles when engaged in research activities involving human subjects.

□ Funding Package does not contain any data collection activities potentially involving human subjects.

MEDAB respectfully requests this memo be included in the funding package for further discussion with the recipient during the official budget discussion with OGS, prior to the final award. Thank you very much, and we look forward to working with *The Regents of the University of California, San Francisco.*

² Funds for preparatory activities (e.g., protocol development, training, equipment, reagents, and site preparation) may be provided prior to protocol approval. To facilitate the availability of preparatory funding, specify a restriction only on funds associated with implementation, and make a note of the preparatory budget in the comments column.

¹ If the activity is strictly for programmatic purposes and will not result in a public report, funds should not be restricted. Provide an activity description and page number, but list \$0 in the Proposed Restriction Amount column.

³ List the cost category of the proposed restriction's budget line. Categories include: Salaries, Fringe Benefits, Consultants, Equipment, Supplies, Travel, Other, Contractual, Direct Costs, and Indirect Costs.

⁴ A copy of the CDC protocol approval (e.g., CGH Project Determination form signed by the CGH Human Research Protection Coordinator, a copy of CDC IRB approval memo) must be included when this technical review is returned to PBEMB. If no CDC approval document is provided, funds for implementing the activity will be restricted.





X By signing below I certify that the country staff has worked through the OGAC Country Support Team Lead (CSTL) to verify that funding to this partner represents 8% or less of the total country budget or OGAC has granted a waiver to the partner for this policy. If a waiver is granted it must be included in the submission of this Funding Package.

Priyanka Rathod

Priyanka Rathod

6/5/2019

Project Officer (printed name)

Project Officer Signature

Date

Wnv9@cdc.gov

404-718-5243

E-mail Address

Phone

Attachment D – Representations and Certification

By signing the Subaward Agreement, the authorized official of Subrecipient certifies, to the best of his/her knowledge and belief that:

Debarment, Suspension, and Other Responsibility Matters: Subrecipient certifies by signing this Subaward Agreement that neither it nor its principals are presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from participation in this transaction by any federal department or agency.

Single Audit Assurance: Subrecipient assures Prime Recipient that it complies with A-133, 45 CFR 75, and/or 2 CFR 200, and that it will notify Prime Recipient of completion of required audits and of any adverse findings which impact this subaward.

Non-Discrimination: The Subrecipient must comply with Title VI of the Civil Rights Act of 1964, Section 504 of the Rehabilitation Act of 1973, the Age Discrimination Act of 1975, Title IX of the Education Amendments of 1972, as amended, and certifies that valid Assurances of Compliance (Form HHS 690) are on file with the HHS Office for Civil Rights.

Statement of Non-Delinquency on Federal Debt: The Subrecipient certifies that it is in compliance with Office of Management and Budget Memorandum M-84-32, "Certification of Non-delinquency by Applicants for Federal Assistance," which provides that the recipient of federal funds is not delinquent on the repayment of any Federal debt.

Scientific Integrity: Subrecipient certifies that the institution has established administrative policies as required by the Final Rule (42 CFR 50, Subpart A), and that it will comply with those policies and the requirements of the Final Rule as published at 54 FR 32446 (August 8, 1989). Expenditures of awarded funds by the Subrecipient for research that are invalid or unreliable because of misconduct in science may be determined to be unallowable costs for which the Subrecipient is liable for repayment.

Certification of a Drug-Free Workplace: The Subrecipient certifies that it has implemented appropriate policy in accordance with the Drug-Free Workplace Act of 1988 as provided in 45 CFR 76, Subpart F.

Gun Control Prohibition (Div. G, Title II, Sec. 217): "None of the funds made available in this title may be used, in whole or in part, to advocate or promote gun control."

Lobbying Restrictions (Div. G, Title V, Sec. 503):

503(a): "No part of any appropriation contained in this Act or transferred pursuant to section 4002 of Public Law 111-148 shall be used, other than for normal and recognized executive-legislative relationships, for publicity or propaganda purposes, for the preparation, distribution, or use of any kit, pamphlet, booklet, publication, electronic communication, radio, television, or video presentation designed to support or defeat the enactment of legislation before the Congress or any State or local legislature or legislative body, except in presentation of the Congress or any State or local legislature itself, or designed to support or defeat any proposed or pending regulation, administrative action, or order issued by the executive branch of any State or local government itself."

503(b): "No part of any appropriation contained in this Act or transferred pursuant to section 4002 of Public Law 111-148 shall be used to pay the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before the Congress or any State government, State legislature or local legislature or legislative body, other than normal and recognized executive legislative relationships or participation by an agency or officer of an State, local or tribal government in policymaking and administrative processes within the executive branch of that government." 503(c): "The prohibitions in subsections (a) and (b) shall include any activity to advocate or promote any proposed, pending or future Federal, State or local tax increase, or any proposed, pending, or future requirement or restriction on any legal consumer product, including its sale of marketing, including but not limited to the advocacy or promotion of gun control."

For additional information, see Additional Requirement 12 at http://www.cdc.gov/grants/additionalrequirements/index.html and Anti Lobbying Restrictions for CDC Grantees at http://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf

Needle Exchange (Div. G, Title V, Sec. 521): "Notwithstanding any other provision of this Act, no funds appropriated in this Act shall be used to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug."

Blocking Access to Pornography (Div. G, Title V, Sec. 526): "(a) None of the funds made available in this Act may be used to maintain or establish a computer network unless such network blocks the viewing, downloading, and exchanging of pornography; (b) Nothing in subsection (a) shall limit the use of funds necessary for any Federal, State, tribal, or local law enforcement agency or any other entity carrying out criminal investigations, prosecution, or adjudication activities."

– ATTACHMENT E

Subaward Number:

Research Subaward Agreement Pass-Through Entity (PTE) Contacts

11626sc

PTE Information								
Entity Name:	The Regents of the University of California, San Francisco							
Legal Address:	3333 California Street, Ste. 315 San Francisco, CA 94143-0962							
Website:	http://osr.ucsf.edu							
PTE Contacts								
Central Email	cgsuboutteam@ucsf.edu							
Principal Investiga	ator Name: George Rutherford							
Email:	George.Rutherford@ucsf.edu Telephone Number:							
Administrative Cor	ntact Name: Judy Li							
Email:	Judy.li2@ucsf.edu Telephone Number:							
COI Contact email	I (if different to above): coiac@ucsf.edu							
Financial Contact	Name: Allison Gesmundo							
Email:	Allison.Gesmundo@ucsf.edu Telephone Number:							
Email invoices?	Yes No Invoice email (if different): subcontract@ucsf.edu							
Authorized Official	Name: Subaward Manager, Research Management Services							
Email:	CGSubOutTeam@ucsf.edu Telephone Number:							
PI Address:								
	3333 California Street, Ste. 315 San Francisco, CA 94153-0962							
Administrative Administrative	ddress:							
	3333 California Street, Ste. 315 San Francisco, CA 94153-0962							
Invoice Address:								
	1855 Folsom Street, #425 San Francisco, CA 94143-0812							

FDP 3A Sept 2017

			Subaward Number:
	Subrecipient C	Contacts	11626sc
Subrecipient Information for FFATA	reporting		
Entity's DUNS Name: 103717336			
EIN No.: 946000417	Institution Type: County C		
DUNS: 103717336		cutive compensation:	es No (if no, complete 3Bpg2)
Parent DUNS:	This section for U.S. Entit		
Place of Performance Address	Congressional District: C	A-12 Zip Code+4	94103-4505
City & County o Department of F 25 Van Ness Av San Francisco,	Public Health /enue, Suite 500		
Subrecipient Contacts			
Central Email:			
Website:	v.sfdph.org		
Principal Investigator Name: Willi	am McFarland		
Email: willi.mcfarland@	sdph.org	Telephone Number: 4	15-437-6251
Administrative Contact Name: Jess	ica Huang		
Email: jessica.huang@	sfdph.org	Telephone Number: 4	15-255-3702
Financial Contact Name:			
Email:		Telephone Number:	
Invoice/Payment Email: davi	d.anabu@sfdph.org		
Authorized Official Name: Tom	as Aragon		
Email: tomas.aragon@	sfdph.org	Telephone Number: 4	15-554-2898
Legal Address:			
City and County of San Francisc Department of Public Health 10 Grove Street San Francisco, CA 94102-4505	:0		
Administrative Address:			
City and County of San Franciso Department of Public Health 1380 Howard Street, 4th floor San Francisco, CA 94103	20		
Payment Address:			
City and County of San Francise Department of Public Health 1380 Howard Street, 4th floor San Francisco, CA 94103	co		

Subaward	Number:
11626sc	

Highest Compensated Officers

Subrecipient:

Institution Name:	San Francisco Department of Public Health
PI Name:	William McFarland

Highest Compensated Officers

The names and total compensation of the five most highly compensated officers of the entity(ies) must be listed if the entity in the preceding fiscal year received 80 percent or more of its annual gross revenues in Federal awards; and \$25,000,000 or more in annual gross revenues from Federal awards; and the public does not have access to this information about the compensation of the senior executives of the entity through periodic reports filed under section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. §§ 78m(a), 78o(d)) or section 6104 of the Internal Revenue Code of 1986. See FFATA § 2(b)(1) Internal Revenue Code of 1986.

Officer 1 Name:	
Officer 1 Compensat	tion:
Officer 2 Name:	
Officer 2 Compensa	tion:
Officer 3 Name:	
Officer 3 Compensa	tion:
Officer 4 Name:	
Officer 4 Compensa	tion:
Officer 5 Name:	
Officer 5 Compensa	tion:

Amendment No. 1 to Agreement No. 11626sc Between The Regents of the University of California And City and County of San Francisco Prime Grant Number: 1 NU2GGH002183-01-04

This Agreement between the Regents of the University of California, on behalf of its San Francisco Campus ("UCSF") and City and County of San Francisco ("Subrecipient") for the project "" is amended as follows:

Article III – Period of Performance

The period of performance is January 1, 2020 through February 29, 2020.

Article IV – Compensation

Additional funding in the amount of \$11,689 is awarded in accordance with Attachment A for the term referenced in Article III, above.

Attachment A – Budget

Attachment B - Award

All other terms and conditions of the Agreement remain in full force and effect.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment on the month, day, and year specified below.

For: The Regents of the University of California

— DocuSigned by:

Phillip Ve Biase

Name:^{Phillip} De Biase

Title: Associate Manager, Subcontracts Date: ^{3/30/2020} For: City and County of San Francisco



03/30/2020 | 12:38

Name: Tomas Aragon

Title: Director of Population Health Division

Date:

Attachment A

San Francisco Department of Public Health Subcontract Budget Period: 1/1/2020-2/29/2020 Budget Name: SIQHIL Burma

<u>A. Salaries and Wages</u> Personnel McFarland, Willi	Position Title Director of Surveillance	Current Salary \$192,300	% effort 25%	# mos. 2	(A) Salary \$8,013	(B) Benefits \$2,424	Total \$10,436 \$0
Total Personnel			25%		\$8,013	\$2,424	\$10,436
Total Direct Costs Overhead at 12% Grand Total							\$10,436 <u>\$1,252</u> \$11,689

Project Name: Burma Cooperative Agreement NU2GGH002183-01-00 San Francisco Department of Public Health (SFDPH) **Budget Justification**

Salaries and Wages:

Willi McFarland, MD, PhD, MPH&TM, Director of Surveillance, Professor and Faculty Advisor, UCSF and Director of the Center for Public Health Research at SFDPH, will provide technical assistance on all surveillance planning and implementation activities in Myanmar, and lead incountry technical trainings/workshops. We request 25% (\$8,013) salary support for this position for 2 months.

Fringe Benefit:

The fringe benefit rate for this subcontract is calculated as follows:

	Salary Requested	% Benefit Rate	Total Fringe Benefits
McFarland, Willi	\$ 8,013	30.25%	\$ 2,424

Total Direct Costs

Indirect Cost Rates:

The indirect cost rate is 12% of total direct expenses and is in compliance with the bilateral agreement between UCSF and SFDPH.

Total: \$11,689

Total: \$10,436

Total: \$2,424

Total: \$1,252

Total: \$8,013

DocuS

uSign Envelope ID: [D5BF4B60-AB0A	-425B-952D-EEE	6FFE424C6 chme	ent B				
1. DATE ISSUED MM/D 01/15/2020	except		ICE dated 01/08/2020 trictions previously imposed ally rescinded	DEPARTMENT OF HEALTH AND HUMAN SERVICES				
2. CFDA NO. 93.067 - Global AIDS				Centers for Disease Control and Prevention CDC Office of Financial Resources				
3. ASSISTANCE TYPE	Cooperative Agreement			 2939 Brandywine Road				
4. GRANT NO. 6 NU2GG Formerly	H002183-01-04	5. TYPE OF AWA Other	RD	Atlanta, GA 30341				
4a. FAIN NU2GGH00218	33	5a. ACTION TYPE	Post Award Amendment					
6. PROJECT PERIOD	MM/DD/YYYY		MM/DD/YYYY	NOTICE OF AWARD				
From	09/30/2019	Through	09/29/2024	AUTHORIZATION (Legislation/Regulations)				
7. BUDGET PERIOD	MM/DD/YYYY		MM/DD/YYYY	42 USC 287b 31 USC 6305 42 CFR 63a				
From	09/30/2019	Through	09/29/2020					
8. TITLE OF PROJECT (Targeted HIV/TB Strat	,	ical Assistance for Pres	ident's Emergency Plan for A	IDS Relief (PEPFAR) and Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) Countries				
9a. GRANTEE NAME AN				9b. GRANTEE PROJECT DIRECTOR				
Regents of the Unive 1855 Folsom St Ste	rsity of California, San	Francisco, The		Dr. GEORGE WILLIAMS RUTHERFORD546030				
San Francisco, CA 9				555 16th Street Box 1224				
San Francisco, CA 9	4143-4249			Institute for Global Health Sciences				
				SAN FRANCISCO, CA 94143-1224				
10a. GRANTEE AUTHOR	IZING OFFICIAL			10b. FEDERAL PROJECT OFFICER				
Ms. Magdalene Cho)			Mrs. Priyanka Rathod				
3333 California Stree	t, Ste 109			12 Corporate Boulevard, NE				
Box 987				Atlanta, GA 30329				

Phone: 404-718-5243

			ALL AMOUNTS ARE	SHOWN IN U	SD					
11. APP	ROVED BUDGET (Exclud	des Direct Assistance)		12. AWARD	COMPUTATION					
I Finar	ncial Assistance from the F	ederal Awarding Agency Only		a. Amount o	of Federal Financial Assistance (from	item 11m)		2,270,633.00		
II Total	project costs including gra	ant funds and all other financial participation	1	b. Less Und	bligated Balance From Prior Budget		0.00			
a.	Salaries and WageS		606.246.00	c. Less Cur	c. Less Cumulative Prior Award(s) This Budget Period 1,62					
	Eringo Bonofito		252 150 00	d. AMOUN	OF FINANCIAL ASSISTANCE THI	S ACTION		647,500.00		
b.	Fringe Benefits		253,150.00	13. Total Fee	deral Funds Awarded to Date for P	roject Period		2,270,633.00		
с.	Total Personnel Cos	ts	859,396.00		IENDED FUTURE SUPPORT					
d.	Equipment		0.00	(Subject to t	he availability of funds and satisfacto	ry progress of the p	project):			
e.	Supplies		11,190.00	YEAR	TOTAL DIRECT COSTS	YEAR	TOTAL	DIRECT COSTS		
			152.336.00	a. 2		d. 5				
T.	Travel		102,000.00	b. 3		e. 6				
g.	Construction		0.00	c. 4		f. 7				
h.	Other		190,036.00	15. PROGRAM ALTERNATIVE	INCOME SHALL BE USED IN ACCORD WITH S:	ONE OF THE FOLLOWIN	NG			
i.	Contractual		617,564.00	a. b.	DEDUCTION ADDITIONAL COSTS			b		
j.	TOTAL DIRECT CO	osts	1,830,522.00	с. d. е.	MATCHING OTHER RESEARCH (Add / Deduct Option) OTHER (See REMARKS)					
k.	INDIRECT COSTS		440,111.00		. ,			-		
				ON THE ABOVE	RD IS BASED ON AN APPLICATION SUBMITTE TITLED PROJECT AND IS SUBJECT TO THE T NCE IN THE FOLLOWING:					
Ι.	TOTAL APPROVED B	JDGET	2,270,633.00	a. b.	The grant program legislation The grant program regulations.					
m.	Federal Share	· · · ·	2,270,633.00	c. This award notice including terms and conditions, if any, noted below under REMARKS. 270,633.00 d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.						
n.	Non-Federal Share		0.00	In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shal prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.						
RE	MARKS (Other Terms	and Conditions Attached -	, [No)						

Admin correction due to sub accounts.

Office of Sponsored Research

GRANTS MANAGEMENT OFFICIAL:

Randolph Williams 2920 Brandywine Rd Mailstop K75 Atlanta, GA 30341-5539 Phone: 770-488-8382

17.0BJ CLA	\SS 41.51	18a. VENDOR CODE	1946036493A6	18b. EIN	946036493	19. DUNS	094878337	20. C	ONG. DIST. 12
FY	-ACCOUNT NO.	DOCU	MENT NO.		ADMINISTRATIVE CODE	AN	IT ACTION FIN ASST		APPROPRIATION
21. а.	9-93904SL	b. 19NU2GG	H00218319HQTB	С.	GH	d.	\$0.00	e.	75-19-0950
22. a.	9-93909D9	b. 19NU2GG	H00218319ABCO	С.	GH	d.	\$0.00	e.	75-19-1721-1031-001
23. a.	9-9390BHZ	b. 19NU2GG	H00218319VNCO	С.	GH	d.	\$0.00	e.	75-19-1822-1031-001

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 2	DATE ISSUED
	01/15/2020

GRANT NO. 6 NU2GGH002183-01-04

EV	ACCOUNT NO.		DOCUMENT NO.		ADMINISTRATIVE CODE	•	MT ACTION FIN ASST		APPROPRIATION
F1-/	ACCOUNT NO.		DOCUMENT NO.		ADIVITINISTRATIVE CODE	A	INT ACTION FIN ASST		AFFROFRIATION
24.a.	9-9390BL2	b.	19NU2GGH002183WHCC	C.	GH	d.	\$0.00	e.	75-19-1822-1031-001
25.a.	0-9390BH9	b.	19NU2GGH00218319CICO	C.	GH	d.	\$0.00	e.	75-19-1822-1031-001
26.a.	0-9390BHZ	b.	19NU2GGH00218319VNCO	C.	GH	d.	\$0.00	e.	75-19-1822-1031-001
27.a.	0-9390DMU	b.	19NU2GGH00218319ABCO	C.	GH	d.	\$0.00	e.	75-19-1923-1031-001
28.a.	0-9390E0Z	b.	19NU2GGH00218319MZCO	C.	GH	d.	\$0.00	e.	75-19-1923-1031-001
29.a.	0-9390DMC	b.	19NU2GGH00218319TZCO	C.	GH	d.	\$0.00	e.	75-19-1923-1031-001
30.a.	0-9390BL2	b.	19NU2GGH00218319WHCC	C.	GH	d.	\$350,000.00	e.	75-19-1822-1031-001
31.a.	0-9390E0V	b.	19NU2GGH00218319WHCC	C.	GH	d.	\$297,500.00	e.	75-19-1923-1031-001

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

Regents Of The University Of California, San Francisco, The

6 NU2GGH002183-01-04

1. terms and conditions

REVISED NOTICE OF COOPERATIVE AGREEMENT

NOTICE OF FUNDING OPPORTUNITY ANNOUNCEMENT (NOFO): GH19-1951 AWARD NUMBER: U2G GH002183-01

Applicable Regulations: 45 Code of Federal Regulations (CFR) Part 75, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for HHS Awards

45 CFR Part 75 supersedes regulations at 45 CFR Part 74 and Part 92

TERMS AND CONDITIONS OF THIS AWARD

PURPOSE: The purpose of this amended Notice of Award is to correct the sub account billing information. This action is for internal billing purposes only.

All other terms and conditions remain unchanged.

PLEASE PROVIDE YOUR AWARD NUMBER ON ALL CORRESPONDENCE.

Amendment No. 2 to Agreement No. 11626sc Between The Regents of the University of California And City and County of San Francisco Prime Grant Number: 1 NU2GGH002183-01-04

This Agreement between the Regents of the University of California, on behalf of its San Francisco Campus ("UCSF") and City and County of San Francisco ("Subrecipient") for the project "" is amended as follows:

Article III – Period of Performance

The period of performance is March 1, 2020 through September 29, 2020.

Article IV – Compensation

Additional funding in the amount of \$40,910 is awarded in accordance with Attachment A for the term referenced in Article III, above.

Attachment A – Budget

Attachment B - Award

All other terms and conditions of the Agreement remain in full force and effect.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment on the month, day, and year specified below.

For: The Regents of the University of California

-Docusigned by: Phillip De Biase

Name: Phillip De Biase

Title: Associate Manager, Subcontracts

Date: 4/28/2020

For: City and County of San Francisco



04/28/2020 | 12:30 PM

Name: Tomas Aragon, MD Title: Director of Population Health Division Date:

Attachment A

San Francisco Department of Public Health Subcontract Budget Period: 3/1/2020-9/29/2020 Budget Name: SIQHIL Burma

<u>A. Salaries and Wages</u> Personnel McFarland, Willi	Position Title Director of Surveillance	Current Salary \$192,300		# mos. 7	(A) Salary \$28,044	(B) Benefits \$8,483	Total \$36,527 \$0
Total Personnel			25%		\$28,044	\$8,483	\$36,527
Total Direct Costs Overhead at 12% Grand Total							\$36,527 <u>\$4,383</u> \$40,910

Salaries and Wages:

Willi McFarland, MD, PhD, MPH&TM, Director of Surveillance, Professor and Faculty Advisor, UCSF and Director of the Center for Public Health Research at SFDPH, will provide technical assistance on all surveillance planning and implementation activities in Myanmar, and lead incountry technical trainings/workshops. We request 25% (\$28,044) salary support for this position for 7 months.

Fringe Benefit:

The fringe benefit rate for this subcontract is calculated as follows:

	Salary Requested	% Benefit Rate	Total Fringe Benefits
McFarland, Willi	\$ 28,044	30.25%	\$ 8,483

Total Direct Costs

Indirect Cost Rates:

The indirect cost rate is 12% of total direct expenses and is in compliance with the bilateral agreement between UCSF and SFDPH.

Total: \$40,910

Total: \$28,044

Total: \$36,527

Total: \$8,483

Total: \$4,383

DocuSign Envelope ID: 9C60320F-89AB-4983-A702-7ED08A45C731

DocuSign Envelope ID: 9C60320F-89AB-4983-A702-7ED08A45C731 ıment B

Through

Through

1. DATE ISSUED <i>MM/DD/YYYY</i> 01/15/2020	1a. SUPERSEDES AWARD NOTICE dated 01/08/2020 except that any additions or restrictions previously imposed remain in effect unless specifically rescinded	DEPARTMENT OF HEALTH AND HUMAN SERVICES					
2. CFDA NO. 93.067 - Global AIDS		Centers for Disease Control and Prevention CDC Office of Financial Resources					
3. ASSISTANCE TYPE Cooperative A	Agreement	2939 Brandywine Road					
4. GRANT NO. 6 NU2GGH002183-01 Formerly	-04 5. TYPE OF AWARD Other	Atlanta, GA 30341					
4a. FAIN NU2GGH002183	5a. ACTION TYPE Post Award Amendment						
6. PROJECT PERIOD MM/DD/	YYYY <i>MM/DD/</i> YYYY	NOTICE OF AWARD					

AUTHORIZATION (Legislation/Regulations)

42 USC 287b 31 USC 6305 42 CFR 63a

8. TITLE OF PROJECT (OR PROGRAM)

09/30/2019

09/30/2019

MM/DD/YYYY

From

From

7. BUDGET PERIOD

Targeted HIV/TB Strategic Information Technical Assistance for President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) Countries

09/29/2024

09/29/2020

MM/DD/YYYY

9a, GRANTEE NAME AND ADDRESS

9a. GRANTEE NAME AND ADDRESS	9b. GRANTEE PROJECT DIRECTOR
Regents of the University of California, San Francisco, The	Dr. GEORGE WILLIAMS RUTHERFORD546030
1855 Folsom St Ste 425	555 16th Street
San Francisco, CA 94143-4249	Box 1224
	Instittute for Global Health Sciences
	SAN FRANCISCO, CA 94143-1224
10a. GRANTEE AUTHORIZING OFFICIAL	10b. FEDERAL PROJECT OFFICER
10a. GRANTEE AUTHORIZING OFFICIAL Ms. Magdalene Cho	10b. FEDERAL PROJECT OFFICER Mrs. Priyanka Rathod
Ms. Magdalene Cho	Mrs. Priyanka Rathod
Ms. Magdalene Cho 3333 California Street, Ste 109	Mrs. Priyanka Rathod 12 Corporate Boulevard, NE

ALL AMOUNTS ARE SHOWN IN USD

11. APP	ROVED BUDGET (Exclude	es Direct Assistance)		12. AWARD	COMPUTATION		
I Finar	icial Assistance from the Fe	ederal Awarding Agency Only	—	a. Amount	of Federal Financial Assistance (fron	n item 11m)	2,270,633.00
II Total	project costs including gra	nt funds and all other financial participation		b. Less Une	obligated Balance From Prior Budget	Periods	0.00
a.	Salaries and WageS		606,246.00	c. Less Cur	nulative Prior Award(s) This Budget I	Period	1,623,133.00
	0			d. AMOUN	T OF FINANCIAL ASSISTANCE TH	IS ACTION	647,500.00
b.	Fringe Benefits		253,150.00	13. Total Fe	deral Funds Awarded to Date for P	roject Period	2,270,633.00
с.	Total Personnel Cost	s	859,396.00		MENDED FUTURE SUPPORT	•	
d.	Equipment		0.00	(Subject to	the availability of funds and satisfacto	ory progress of the p	project):
e.	Supplies		11,190.00	YEAR	TOTAL DIRECT COSTS	YEAR	TOTAL DIRECT COSTS
f	Travel		152.336.00	a. 2		d. 5	
1.	Haver		,	b. 3		e. 6	
g.	Construction		0.00	c. 4		f. 7	
h.	Other		190,036.00	15. PROGRAM	I INCOME SHALL BE USED IN ACCORD WITH	ONE OF THE FOLLOWIN	NG
i.	Contractual		617,564.00	a. b.	DEDUCTION ADDITIONAL COSTS		b
j.	TOTAL DIRECT CO	STS	1,830,522.00	c. d. e.	MATCHING OTHER RESEARCH (Add / Deduct Option) OTHER (See REMARKS)		
k.	INDIRECT COSTS		440,111.00	-	RD IS BASED ON AN APPLICATION SUBMITT		
				ON THE ABOVE	TITLED PROJECT AND IS SUBJECT TO THE T		
١.	TOTAL APPROVED BU	DGET	2,270,633.00	a. b.	The grant program legislation The grant program regulations.		
m.	Federal Share		2.270.633.00	с. d.	This award notice including terms and condition Federal administrative requirements, cost princ	ns, if any, noted below und tiples and audit requirement	er REMARKS. ts applicable to this grant.
							e grant, the above order of precedence shall
n.	Non-Federal Share		0.00		tance of the grant terms and conditions is a the grant payment system.	cknowledged by the gra	ntee when tunds are drawn or otherwise
RE	MARKS (Other Terms a	nd Conditions Attached - Yes	Γ	No)			

Admin correction due to sub accounts.

GRANTS MANAGEMENT OFFICIAL:

Randolph Williams 2920 Brandywine Rd Mailstop K75 Atlanta, GA 30341-5539 Phone: 770-488-8382

17.0BJ CL	ASS 41.51	18a. VENDOR CODE	1946036493A6	18b. EIN	946036493	19. DUNS	094878337	20. 0	CONG. DIST. 12
F	Y-ACCOUNT NO.	DOCUI	MENT NO.		ADMINISTRATIVE CODE	AM	IT ACTION FIN ASST		APPROPRIATION
21. а.	9-93904SL	b. 19NU2GGł	100218319HQTB	C.	GH	d.	\$0.00	e.	75-19-0950
22. a.	9-93909D9	b. 19NU2GGH	100218319ABCO	C.	GH	d.	\$0.00	e.	75-19-1721-1031-001
23. a.	9-9390BHZ	b. 19NU2GGH	100218319VNCO	C.	GH	d.	\$0.00	e.	75-19-1822-1031-001

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 2	DATE ISSUED
	01/15/2020

GRANT NO. 6 NU2GGH002183-01-04

			DOOL IMENT NO			•			
FY-/	ACCOUNT NO.		DOCUMENT NO.	F	ADMINISTRATIVE CODE	A	MT ACTION FIN ASST		APPROPRIATION
24.a.	9-9390BL2	b.	19NU2GGH002183WHCC	C.	GH	d.	\$0.00	e.	75-19-1822-1031-001
25.a.	0-9390BH9	b.	19NU2GGH00218319CICO	C.	GH	d.	\$0.00	e.	75-19-1822-1031-001
26.a.	0-9390BHZ	b.	19NU2GGH00218319VNCO	C.	GH	d.	\$0.00	e.	75-19-1822-1031-001
27.a.	0-9390DMU	b.	19NU2GGH00218319ABCO	c.	GH	d.	\$0.00	e.	75-19-1923-1031-001
28.a.	0-9390E0Z	b.	19NU2GGH00218319MZCO	C.	GH	d.	\$0.00	e.	75-19-1923-1031-001
29.a.	0-9390DMC	b.	19NU2GGH00218319TZCO	C.	GH	d.	\$0.00	e.	75-19-1923-1031-001
30.a.	0-9390BL2	b.	19NU2GGH00218319WHCC	c.	GH	d.	\$350,000.00	e.	75-19-1822-1031-001
31.a.	0-9390E0V	b.	19NU2GGH00218319WHCC	C.	GH	d.	\$297,500.00	e.	75-19-1923-1031-001

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

Regents Of The University Of California, San Francisco, The

6 NU2GGH002183-01-04

1. terms and conditions

REVISED NOTICE OF COOPERATIVE AGREEMENT

NOTICE OF FUNDING OPPORTUNITY ANNOUNCEMENT (NOFO): GH19-1951 AWARD NUMBER: U2G GH002183-01

Applicable Regulations: 45 Code of Federal Regulations (CFR) Part 75, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for HHS Awards

45 CFR Part 75 supersedes regulations at 45 CFR Part 74 and Part 92

TERMS AND CONDITIONS OF THIS AWARD

PURPOSE: The purpose of this amended Notice of Award is to correct the sub account billing information. This action is for internal billing purposes only.

All other terms and conditions remain unchanged.

PLEASE PROVIDE YOUR AWARD NUMBER ON ALL CORRESPONDENCE.



London N. Breed Mayor

TO: Angela Calvillo, Clerk of the Board of Supervisors

FROM: Dr. Grant Colfax Director of Health

DATE: 6/9/2021

SUBJECT: Grant Accept and Expend

GRANT TITLE: Accept and Expend Grant - Targeted HIV/TB Strategic Information Technical Assistance for President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) Countries - \$127,696

Attached please find the original and 1 copy of each of the following:

- Proposed grant resolution, original signed by Department
- Grant information form, including disability checklist -
- Budget and Budget Justification
- Grant application: Not Applicable. No application submitted.
- Agreement / Award Letter
- Other (Explain): Amendments

Special Timeline Requirements:

Departmental representative to receive a copy of the adopted resolution:

Name: Gregory Wong (greg.wong@sfdph.org)	Phone: 554-2521
Interoffice Mail Address: Dept. of Public Health, 101	Grove St # 108
Certified copy required Yes	No 🖂